

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Disseminated gonococcal infection associated with *Neisseria gonorrhoeae* genotypes harbouring the PIA class of porB in Queensland, Australia

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-061040
Article Type:	Original research
Date Submitted by the Author:	14-Jan-2022
Complete List of Authors:	Guglielmino, Christine; Health Support Queensland Forensic and Scientific Services Sandhu, Sumeet; Health Support Queensland Forensic and Scientific Services Lau, Colleen L.; Australian National University Research School of Population Health Buckely, Cameron; UQ Centre for Clinical Research, University of Queensland Trembizki, Ella; UQ Centre for Clinical Research, University of Queensland Whiley, David; UQ Centre for Clinical Research, University of Queensland Jennison, Amy; Health Support Queensland Forensic and Scientific Services
Keywords:	Epidemiology < TROPICAL MEDICINE, INFECTIOUS DISEASES, MOLECULAR BIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1 1 **Disseminated gonococcal infection associated with *Neisseria gonorrhoeae* genotypes harbouring the PIA**
2
3 2 **class of *porB* in Queensland, Australia**

4
5
6
7 3 Running Title: DGI and *porB* genotype

8
9
10 4 Christine J. D. Guglielmino¹, Sumeet Sandhu¹, Colleen L. Lau^{2,3}, Cameron Buckley⁴, Ella Trembizki⁴, David M.
11
12 5 Whiley⁴, Amy V. Jennison^{1*}

13
14
15 6 ¹Public Health Microbiology, Queensland Health Forensic and Scientific Services, Brisbane, Australia

16
17
18 7 ²Research School of Population Health, Australian National University, Canberra, Australia

19
20
21
22 8 ³School of Public Health, University of Queensland, Brisbane, Australia

23
24
25 9 ⁴UQ Centre for Clinical Research, University of Queensland, Brisbane, Australia

26
27
28 10 *Corresponding Author: Amy.Jennison@health.qld.gov.au PO Box 594, Archerfield, Queensland 4108,
29
30 11 Australia. Telephone: +61730962821 fax: +61730962973

31
32
33 12 **Abstract word count:227**

34
35
36
37 13 **Text word count: 2113**

38
39
40 14

41
42
43 15

44
45
46 16

47
48
49 17

50
51
52 18

53
54
55 19

20 **ABSTRACT**

1
2
3 21 **Objectives.** Gonorrhoea caused by *Neisseria gonorrhoeae* is the second most notified sexually transmitted
4
5 22 infection in Australia and case numbers for this STI have been increasing globally. Progressive gonococcal
6
7 23 infection may lead to Disseminated gonococcal infection (DGI) which causes significant morbidity among
8
9 24 patients. This study aimed to examine the genetic diversity of *N. gonorrhoeae* isolates collected in Queensland
10
11 25 from January 2010 to August 2015 and to determine factors associated with DGI in Queensland.
12
13
14

15 26 **Methods.** Between January 2010 and August 2015, 3953 *Neisseria gonorrhoeae* isolates from both
16
17 27 metropolitan and regional Queensland infections were typed with NG-MAST (*N. gonorrhoeae* multi antigen
18
19 28 sequence typing) to assess the genetic diversity between strains. Whole genome sequencing (WGS) was used
20
21 29 to investigate strain related factors associated with DGI.
22
23
24

25 30 **Results.** ST6876 was the most common NG-MAST type, detected in 7.6% of the isolates. DGI was significantly
26
27 31 more likely in females <30 years (OR 13.02, $p < 0.0001$) and in older males >30 years (OR 6.04, $p < 0.0001$), with
28
29 32 most cases originating from North Queensland (OR 8.5, $p < 0.0001$). Strains harbouring PIA class of *porB* type
30
31 33 were associated with DGI (OR 33.23, $p < 0.0001$). WGS demonstrated that NG-MAST types having a *plgA* phase
32
33 34 variation were more commonly detected in DGI.
34
35
36

37 35 **Conclusion.** Genotyping techniques such as NG-MAST and WGS are proving instrumental in providing an insight
38
39 36 into the population structure of *N. gonorrhoeae*, and genetic mechanisms of pathogenesis, such as for DGI.
40
41
42

43 37 **Keywords:** *Neisseria gonorrhoeae*; Gonorrhoea; DGI; Australia; Genotype; NG-MAST; WGS
44
45
46

47 38

49 39

53 40

56 41

Strengths and Limitations of this study

- This study investigated the burden of gonococcal infections in Queensland and identified those most at risk of developing DGI.
- Young women (<30 years) and older men (>30 years) were determined to be at higher risk of developing DGI.
- The PIA class of *porB* type was determined to be more common in the DGI cohort.
- The NG-MAST genotyping was performed on a large, diverse, consecutively collected *N. gonorrhoeae* isolate collection that encompassed both metropolitan and regional populations, which would assist in best capturing high risk populations for DGI.
- Only a small number of isolates were subject to whole genome sequencing so no statistical significance can be drawn from analysis of *plgA* phase variation and role of the gonococcal genetic island.

INTRODUCTION

Disseminated gonococcal infection (DGI) is a complication of gonorrhoea from bacteraemic spread of *Neisseria gonorrhoeae*. It typically presents as an arthritis-dermatitis syndrome but in rare cases can lead to death via septic shock [1]. DGI primarily occurs in individuals with an asymptomatic untreated primary infection, most often female, although some studies have shown an association with males [2-4]. Early diagnosis and treatment are required to avert significant morbidity.

Both host and *N. gonorrhoeae* strain-related factors can predispose to DGI. Host associated risk factors include recent menstruation, pregnancy and complement deficiencies [5-7]. Several strain-related factors have been proposed including exhibiting an arginine-hypoxanthine-uracil (AHU) auxotype, expressing particular phase-variable variants of the pilus glycosyl transferase A (*pgtA*) gene, opacity genes, and harbouring a PIA class of *porB* gene (as opposed to PIB) [8-14]. Gonococcal genetic island (GGI) is another speculated virulence factor encoding a Type IV secretion system (T4SS) which plays a role in horizontal gene transfer [15]. However, except for the PIA gene, evidence to support the strain-related factors is limited. For example, an early study of DGI-causing gonococci in Australia found that none were of the AHU auxotype, while a later Australian study found

68 no strong association with the phase-variable allele of the *pgtA* gene, subsequently referred to as the *pgIA*
69 gene [16,17]. Previous studies assessing strain-related factors associated with DGI are limited by sample size
70 and/or lack of comparison to non-DGI isolates.

71 We sought to assess the genetic diversity of *N. gonorrhoeae* isolates collected in Queensland from January
72 2010 to August 2015 and to determine factors associated with DGI in Queensland. In addition, we utilised WGS
73 to gain insight to any existing strain-related factors which may have contributed to the occurrence of DGI.

74 METHODS

75 *N. gonorrhoeae* isolates from Queensland

76 From 2010 to 2015, the Australian state of Queensland reported 16,506 gonococcal infections over the 6 years,
77 equivalent to an average notification rate of 60 cases per 100,000 population per year [18]. Approximately 75%
78 of these notifications were diagnosed by NAAT only, with no isolate available for further testing. Diagnostic
79 methods used varied across the state, with 80% of cases in the northern Queensland regions diagnosed by
80 NAAT only, as opposed to 70% of cases from the rest of the state; with larger variations of between 58% and to
81 84% for individual health service districts. A total of 3953 *N. gonorrhoeae* isolates were included in this study,
82 isolated from specimens collected between January 2010 and August 2015 in pathology laboratories servicing
83 Queensland and surrounding areas and subsequently referred to the state reference laboratory at Queensland
84 Health Forensic and Scientific Services. One isolate per patient episode, defined as not collected within one
85 month of a previously included strain, was included. Data collected for each isolate included date of specimen
86 collection, age, sex, postcode of residence and specimen type. To identify disease prevalence in specific age
87 groups isolates from males and females were grouped into two groups, <30 years and ≥30 years. Postcode of
88 residence was used to assign broad geographic region categories of NQ (northern Queensland) and SEQ (south-
89 east Queensland) and other (sparsely populated central Queensland, interstate, or overseas). DGI was defined
90 where the organism was isolated from blood culture, joint fluid and/or tissue.

91 NG-MAST typing and Phylogenetic analysis

92 Crude DNA extracts of all the *N. gonorrhoeae* isolates received in the study period were routinely subjected to
93 *N. gonorrhoeae* multi-antigen sequence typing (NG-MAST) as previously described [19]. These extracts were
94 prepared by boiling 400µL of TE buffer containing a loopful (1µL) of pure *N. gonorrhoeae* colonies at 100°C for
95 10 minutes. NG-MAST comprises DNA sequencing of partial *tbpB* and *porB* genes and subsequent analysis via
96 an online database to assign allele and sequence types (www.ng-mast.net). The *porB* sequence data from the
97 NG-MAST was analysed to assign either PIA or PIB class [20]. *porB* and *tbpB* sequences were concatenated for
98 each different NG-MAST, aligned in Geneious R11 with MUSCLE [21] and a maximum likelihood phylogenetic
99 tree was generated with RAxML software version 8.0 [22].

100 **WGS and Bioinformatic analysis**

101 To investigate strain-related factors associated with DGI, we selected 16 isolates from 8 different NG-MAST
102 types which were prevalent in DGI, in this study. Two strains from each NG-MAST were selected, comprising
103 both DGI and non-DGI strains. DNA was extracted from isolates using the QIAasymphony SP, using the DSP DNA
104 minikit (Qiagen, Germany), as per manufacturer's guidelines. WGS was performed on the Illumina NextSeq 500
105 platform (Illumina, CA, USA) using NextSeq 500 Mid Output V2 kit (Illumina) with Nextera XT library
106 preparation. Reads were trimmed with Trimmomatic [23], corrected and assembled with Spades [24], and
107 assemblies uploaded to pubMLST to determine presence/absence of the gonococcal genetic island, and
108 analysed with Ridom SeqSphere+ (Ridom GmbH, Germany) using alleles from 1,649 *N. gonorrhoeae* cgMLST
109 v1.0 loci [25], and *Neisseria* spp. MLST [26]. WGS assemblies are available on pubMLST with ID numbers 52753-
110 52768.

111 **Statistical Analysis**

112 Descriptive analysis was performed using Microsoft Excel. Annual rates of reported cases were computed by
113 using the number of cases reported as numerators, and statistics Queensland yearly population as
114 denominators. Categorical variables were examined using the Fischer's Exact test performed in GraphPad Prism
115 7(GraphPad Software Inc., California). Odds ratios (OR) with 95% confidence intervals were obtained from

116 logistic regression models in Microsoft Excel to quantify associations between independent variables and
 117 outcome. P values of <0.05 were considered statistically significant.

118 Patient and Public Involvement

119 No patients involved.

120 RESULTS

121 Demographics and *N. gonorrhoeae* isolates

122 The total 3,953 *N. gonorrhoeae* isolates in this study from January 2010 to August 2015 consisted of genital
 123 (n=3,099; 78.3%), invasive (n=64; 1.6%), anorectal (n=456; 11.5%), oropharyngeal (n=233; 5.8%), ocular (n=31;
 124 0.7%), and other/not specified (n=70; 1.7%) specimen types, as listed in Supplementary Data Table 1. Overall,
 125 majority of these isolates were reported in SEQ (n= 2403; 60.7%), followed by NQ (n=1193; 30.1%) and other
 126 regions (sparsely populated central Queensland, interstate, or overseas) which constituted of 9% (n=357) of
 127 the total cases. The isolates comprised 73% (n=2898) from males (62.9 cases per 100,000 population) and 27%
 128 (n=1055) from females (22.9 cases per 100,000 population). Further breakdown into age groups showed that
 129 20.4% (n=808) gonococcal infections were represented by females <30 years of age and 5.9% of infections
 130 were reported in females ≥30 years of age. Similar trend was observed in males where 44.3% (n=1754) of *N.*
 131 *gonorrhoeae* infections were noted in males <30 year of age and 28.3% (n=1119) of infections were present in
 132 males ≥30 years of age. PIB class of *porB* was assigned to 72.7% (n=2875) of isolates whereas 27.3% (n=1078)
 133 of the isolates belonged to *porB* class PIA. Table 1 shows a breakdown for all strains by PIA/PIB, NQ/SEQ, and
 134 age group.

135 **Table 1: Demographics of *N. gonorrhoeae* isolates, Queensland January 2010 to August 2015. Created by the**
 136 **authors.**

Demographics	n	Percentage (%) of total
All cases	3953	100

porB Class	PIA	1078	27.3
	PIB	2875	72.7
Geographic location	NQ	1193	30.1
	SEQ	2403	60.7
	Others	357	9.0
Sex	F	1055	26.6
	M	2898	73.3
Age groups	<30 Female	808	20.4
	≥30 Female	1754	44.3
	<30 Male	234	5.9
	≥30 Male	1119	28.3
	Age not specified	38	0.9

138 NG-MAST typing and Phylogenetic analysis

139 Among the 3,953 isolates tested, 574 alleles of *porB* gene were identified, the most prevalent of which was
 140 ST4101, present in 441 isolates (11.1%). The *tbpB* gene was represented by 250 alleles with the most frequent
 141 allele was 29, detected in 653 isolates (16.5%). Combinations of *porB* and *tbpB* alleles resulted in 823 NG-MAST
 142 types. Overall ST6876 was the most common NG-MAST type, detected in 302 isolates (7.6%). It was also the
 143 most prevalent in years 2010 and 2011, represented by 126 (16.1%) and 109 (14.4%) isolates, respectively. In
 144 2012 and 2013, ST21 became more prevalent, represented by 8.6% and 6.0% of the isolates collected in those
 145 years. In 2014 and 2015 (up to August), ST4186 was found with high frequency with 7.1% and 10.1% of the
 146 isolates, respectively. 771 STs were represented by only one isolate, and these STs accounted for between
 147 16.8% and 23.3% of total isolates each year. Table 2 shows a summary of the most frequent alleles and types
 148 over the five years.

150
1
2
3 151
4
5
6
7 152
8
9
10 153
11
12
13 154
14
15
16 155
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

156 **Table 2: NG-MAST typing of isolates collected in Queensland from January 2010 to August 2015. Created by the authors.**

Year	Number of <i>N. gonorrhoea</i> isolates	Number of <i>porB</i> alleles	Most frequent <i>porB</i> alleles	Number of <i>tbpB</i> alleles	Most frequent <i>tbpB</i> alleles	Number of NG-MAST types	Most frequent NG-MAST types	<i>porB</i> Class	Invasive (DGI) isolates *
2010	782	165	porB 4101 (18.7%)	87	tbpB 29 (17.6%)	208	6876 (16.1%)	PIA - 255 (32.6%) PIB - 527 (67.3%)	12 (1.5%)
			porB 2280 (5.3%)		tbpB 1330 (16.3%)		6863 (5.4%)		
			porB 908 (4.7%)		tbpB 1329 (8.4%)		1407 (4.7%)		
			porB 1808 (4.4%)		tbpB 110 (6.6%)		2992 (4.4%)		
			porB 4143 (3.7%)		tbpB 349 (6.1%)		6940 (3.7%)		
2011	754	157	porB 4101 (17.9%)	85	tbpB 29 (24.0%)	206	6876 (14.4%)	PIA - 240 (31.8%) PIB - 514 (68.1%)	8 (1.0%)
			porB 1808 (8.8%)		tbpB 1330 (15.5%)		2992 (8.8%)		
			porB 4099 (5.3%)		tbpB 349 (7.0%)		6879 (4.7%)		
			porB 14 (4.7%)		tbpB 33 (6.7%)		21 (4.4%)		
			porB 4104 (3.7%)		tbpB 1329 (6.1%)		6937 (3.2%)		
2012	680	156	porB 4101 (12.2%)	91	tbpB 29 (19.7%)	203	21 (8.6%)	PIA - 195 (28.6%) PIB - 485 (71.3%)	10 (1.4%)
			porB 14 (8.6%)		tbpB 349 (12.3%)		2992 (7.6%)		
			porB 4099 (7.7%)		tbpB 33 (10.8%)		6879 (7.5%)		
			porB 1808 (7.6%)		tbpB 1330 (9.1%)		6876 (7.0%)		
			porB 4104 (5.5%)		tbpB 1329 (7.0%)		6937 (4.1%)		
2013	650	167	porB 1808 (7.2%)	93	tbpB 29 (18.9%)	217	21 (6.0%)	PIA - 160 (24.6%) PIB - 490 (75.3%)	10 (1.5%)
			porB 4101 (6.7%)		tbpB 349 (8.3%)		4822 (6.0%)		
			porB 1903 (6.1%)		tbpB 33 (7.5%)		6879 (5.3%)		
			porB 14 (6.0%)		tbpB 110 (6.9%)		4186 (5.2%)		
			porB 4099 (5.3%)		tbpB 241 (6.9%)		5533 (4.0%)		
2014	633	147	porB 1808 (14.6%)	90	tbpB 241 (8.5%)	201	4186 (7.1%)	PIA - 140 (22.1%) PIB - 493 (77.8%)	18 (2.8%)
			porB 2569 (7.2%)		tbpB 29 (7.8%)		9654 (5.6%)		
			porB 147 (6.4%)		tbpB 4 (7.1%)		4244 (4.8%)		
			porB 4101 (4.5%)		tbpB 110 (6.1%)		10039 (3.7%)		
			porB 5912 (3.7%)		tbpB 1744 (6.0%)		5004 (2.3%)		
2015**	454	115	porB 1808 (12.1%)	74	tbpB 241 (16.5%)	154	4186 (10.1%)	PIA - 87 (19.1%) PIB - 367 (80.8%)	6 (1.3%)
			porB 2569 (10.1%)		tbpB 4 (6.4%)		4244 (5.2%)		
			porB 147 (8.14%)		tbpB 29 (5.9%)		9654 (4.4%)		
			porB 2656 (5.0%)		tbpB 893 (5.7%)		9909 (3.9%)		
			porB 543(4.1%)		tbpB 1744 (5.3%)		11821 (3.7%)		

*percentage of total isolates

**Data Collected up until August 2015

Disseminated Gonococcal Infection

From January 2010 to August 2015, 64 DGI-related isolates were received by the reference laboratory, comprising 1.6% of total isolates; 49 cases (76.6%) were diagnosed from joint samples and 15 (23.4%) from blood samples. This study only had access to cultured gonococcal isolates, so any DGI cases diagnosed by NAAT only are not considered here. A summary of the demographics, *porB* class types and strain types (n=8) associated with DGI cases is provided in Table 3. Even though the majority of total gonococcal isolates were from males, DGI was significantly more likely in females (OR 4.72, $p<0.0001$), particularly in those aged <30 years (OR 13.02, $p<0.0001$) and in older males aged >30 years (OR 6.04, $p<0.0001$) when compared to their younger counterparts. The majority of DGI cases (n=50; 78%) originated from the north Queensland, and cases from this region had higher odds of being associated with DGI (OR 8.5, $p<0.0001$). A total of 31 STs of the total 823 were observed amongst the 64 DGI cases. PIA *porB* type was significantly associated with DGI (OR 33.23, $p<0.0001$), and accounted for 59 (92.2%) of the 64 DGI cases. Seven of the prevalent NG-MASTs in DGI (ST758, ST6886, ST6937, ST6939, ST7126, ST8712, and ST10711), all with PIA class of *porB*, were found to be individually associated with DGI (Table 3). However, the most prevalent NG-MAST in this study ST6876 (n=302), which is also PIA class of *porB*, was not found to be associated with DGI (n=6) (OR 1.2, $p=0.6$).

Table 3: Demographic factors, *porB* type and NG-MAST types associated with disseminated gonococcal infection (DGI) in Queensland (January 2010 to August 2015). Created by the authors.

Risk factor		Non-DGI	DGI	Total	DGI as percentage (%)	Univariate OR	p value
porB class	PIA	1019	59	1078	5.5	33.23	<0.0001
	PIB	2870	5	2875	0.2	0.03	
Geographic location	NQ	1143	50	1193	4.2	8.5	<0.0001
	SEQ	2394	9	2403	0.4	0.1	
	Other	352	5	357	1.4	0.85	
Sex	Female	1015	40	1055	3.8	4.72	<0.0001
	Male	2874	24	2898	0.8	0.2	
Age group (years)	<30 Female	779	29	808	3.58	13.02	<0.0001
	<30 Male	1749	5	1754	0.2	0.07	
	≥30 Female	223	11	234	4.7	2.85	0.01
	≥30 Male	1100	19	1119	1.69	0.35	
	<30 Female	779	29	808	3.58	0.75	0.44
	≥30 Female	223	11	234	4.7	1.32	
	<30 Male	1749	5	1754	0.2	0.16	<0.0001
	≥30 Male	1100	19	1119	1.69	6.04	
	Age not specified	38	0	38	0.0		
Prevalent NG-MAST	ST758	17	2	19	10.5	3.67	0.03
	ST6876	296	6	302	2.0	1.2	0.6

types	ST6886	30	3	33	9.1	6.3	0.001
	ST6937	80	14	94	14.9	13.3	<0.0001
	ST6939	34	3	37	8.1	5.57	0.02
	ST7126	22	3	25	12.0	8.6	0.007
	ST8712	17	5	22	22.7	19.3	<0.0001
	ST10711	15	3	18	16.7	12.7	0.002
	Other STs	3378	25	3403	0.7	0.09	
	Total	3889	64	3953	1.6%		

Whole Genome Sequencing

Figure 1 shows a core genome phylogeny of the 16 strains from 8 different NG-MAST, all of which were PIA types, selected for WGS. The four ST6886 and ST6937 strains contained phase variable *pglA* (NEIS0213) alleles with long homopolymeric tracts of Gs, while the others did not. These four strains grouped together by cgMLST, despite one of them sharing an MLST profile with other strains that did not form part of this group. Only one of the 16 strains sequenced did not possess the gonococcal genetic island.

DISCUSSION

This study investigated the burden of gonococcal infections in Queensland and identified those most at risk of developing DGI. The increasing gonorrhoea rates among males could be a result of rapidly increasing rates of gonorrhoea in the MSM population. Another explanation would be that gonorrhoea is more symptomatic in men and as a result they are more likely to seek health care. In this study, we applied *N. gonorrhoeae* NG-MAST genotyping to a large, diverse, consecutively collected *N. gonorrhoeae* isolate collection in a setting where DGI is not uncommon and used WGS to investigate other strain-related factors. We have used a dataset of strains that encompassed both metropolitan and regional populations and has subsequently highlighted different populations vulnerable to DGI. We observed a higher likelihood of DGI in females, in cases reported in NQ

1
2 198 when compared to SEQ, and with strains harbouring the PIA gene. This finding agrees with previous studies
3
4 199 suggesting female predominance [2] but contradicts a more recent study from the Northern Territory of
5
6 200 Australia which did not show any significant association between DGI and sex [15], but did not examine strain-
7
8 201 related factors such as PIA/PIB. Moreover, our data may indicate that DGI is associated with certain PIA gene
9
10
11 202 positive NG-MAST types, suggesting that additional mechanisms possessed by particular PIA bearing genotypes
12
13 203 may be at play. PIA has previously been reported to be associated with DGI due to a diminished inflammatory
14
15 204 response, which increases the chances that a mucosal infection may go untreated and therefore progress to
16
17
18 205 DGI [27].
19

20
21 206 Our data identified *plgA* phase variation present within certain NG-MAST types that were associated with DGI,
22
23 207 however further studies with larger diversity of strain collections are required, as this finding is inconsistent
24
25 208 with the work of Power *et al* [17]. Our sequencing work did not show any evidence that DGI is associated with
26
27
28 209 the gonococcal genetic island as seen by Dillard *et al* [15], however with the limited number of strains we
29
30 210 sequenced, no statistical significance can be drawn and further studies are required to confirm or refute this.
31
32 211 Data on the co-existence of genital infections for DGI cases was not consistently available, however there were
33
34 212 DGI cases that did not have a genital infection recorded in the dataset. Absence of a genital infection suggests
35
36
37 213 cases may have cleared a mucosal infection before progressing to DGI, which would be more likely for
38
39 214 asymptomatic infections in females rather than via anorectal injury infection in males.
40

41
42 215 The majority of gonorrhoea cases yielding an isolate are represented by males who continue to have higher
43
44 216 notification rates than females in Queensland. DGI is not a rare occurrence, being noted in 1.6% of culture-
45
46
47 217 positive cases, and younger females showing higher rates than males. High DGI rates among younger women
48
49 218 are concerning as infertility is one of the potential outcomes of untreated gonorrhoea infection, which has
50
51 219 downstream social and economic impacts. Genotyping techniques such as NG-MAST and WGS are proving
52
53 220 instrumental in providing an insight into the population structure of *N. gonorrhoeae*, and genetic mechanisms
54
55 221 of pathogenesis, such as for DGI.
56
57
58
59
60

1
2 222 **Contributorship statement**
3
4

5 223 Amy Jennison and David Whiley conceptualised the study. Christine Guglielmino conducted the laboratory
6
7 224 investigation. Christine Guglielmino, Sumeet Sandhu, Colleen Lau and Ella Trembizki performed formal data
8
9 225 analysis. All authors contributed to the writing and review of the manuscript.
10
11
12

13 226 **Acknowledgments**
14
15

16 227 This publication made use of the Neisseria Multi Locus Sequence Typing website ([https://pubmlst.org/](https://pubmlst.org/neisseria/)
17
18 228 [neisseria/](https://pubmlst.org/neisseria/)) developed by Keith Jolley and sited at the University of Oxford [28]. The development of this site
19
20 229 has been funded by the Wellcome Trust and European Union. We thank all laboratories for referring isolates
21
22
23 230 included in this study, and Public Health Microbiology Staff for technical work.
24
25

26 231 **Conflicts of interest. None**
27
28

29 232 **Data Availability**
30
31

32 233 No additional data available
33
34
35

36 234 **Funding:** This research did not receive any specific grant from funding agencies in the public, commercial, or
37
38 235 not-for-profit sectors.
39
40

41 236 **Corresponding Author:** Amy.Jennison@health.qld.gov.au PO Box 594, Archerfield, Queensland 4108, Australia.
42

43 237 Telephone: +61730962821 fax: +61730962973
44
45
46

47 238 **Transparency declarations:** D.M.W. reports research funding from SpeeDx Pty Ltd and is supported by a
48
49 239 Queensland Advancing Clinical Research Fellowship from the Queensland Government. E.T is holding an
50
51 240 NHMRC Early Career Fellowship. CLL is supported by an NHMRC Investigator Grant (APP1193826).
52
53

54 241 **Ethics Approvals:** The study was approved by Forensic and Scientific Services Human Ethics Committee (FSS-
55
56 242 HEC, EC00305). HEC Ref Number HEC18_01.
57
58
59
60

1
2 243 **REFERENCES**
3
4

- 5 244 1 Thiéry G, Tankovic J, Brun-Buisson C, et al. Gonococemia associated with fatal septic shock. *Clin Infect Dis*
6
7 245 2001;32:92-93.
8
9
10
11 246 2. Tuttle CS, Van Dantzig T, Brady S, et al. The epidemiology of gonococcal arthritis in an Indigenous Australian
12
13 247 population. *Sex Transm Infect* 2015;91:497-501.
14
15
16 248 3. Suzaki A, Hayashi K, Kosuge K, et al. Disseminated gonococcal infection in Japan: a case report and literature
17
18 249 review. *Inter Med* 2011;50:2039-2043.
19
20
21
22 250 4. Belkacem A, Caumes E, Ouanich J, et al. Changing patterns of disseminated gonococcal infection in France:
23
24 251 cross-sectional data 2009–2011. *Sex Transm Infect* 2013; 9:613-615.
25
26
27 252 5. Bleich AT, Sheffield JS, Wendel Jr GD, et al. Disseminated gonococcal infection in women. *Obstet Gynecol*
28
29 253 2012;119:597-602.
30
31
32
33 254 6. Phupong V, Sittisomwong T, Wisawasukmongchol W. Disseminated gonococcal infection during pregnancy.
34
35 255 *Gynecol and Obstet* 2005;273:185-186.
36
37
38 256 7. Petersen BH, Lee TJ, Snyderman R, et al. *Neisseria meningitidis* and *Neisseria gonorrhoeae* bacteremia
39
40 257 associated with C6, C7, or C8 deficiency. *Annals Int Med* 1979;90:917-920.
41
42
43
44 258 8. Banerjee A, Wang R, Supernavage SL, et al. Implications of phase variation of a gene (*pgtA*) encoding a pilin
45
46 259 galactosyl transferase in gonococcal pathogenesis. *J of Exp Med* 2002;196 (2):147-162.
47
48
49 260 9. Roth A, Mattheis C, Muenzner P, et al. Innate recognition by neutrophil granulocytes differs between
50
51 261 *Neisseria gonorrhoeae* strains causing local or disseminating infections. *Infect Immun* 2013;81:2358-2370.
52
53
54
55 262 10. Knapp JS, Holmes KK. Disseminated gonococcal infections caused by *Neisseria gonorrhoeae* with unique
56
57 263 nutritional requirements. *J Infect Dis* 1975;132:204-208.
58
59
60

- 1
2 264 11. Brunham RC, Plummer F, Slaney L, et al. Correlation of auxotype and protein I type with expression of
3
4 265 disease due to *Neisseria gonorrhoeae*. *J Infect Dis* 1985;152:339-343.
5
6
7 266 12. van Putten JP, Duensing TD, Carlson J. Gonococcal invasion of epithelial cells driven by P. IA, a bacterial ion
8
9
10 267 channel with GTP binding properties. *J Exp Med* 1998;188:941-952.
11
12
13 268 13. Plummer FA, Chubb H, Simonsen JN, et al. Antibodies to opacity proteins (Opa) correlate with a reduced
14
15 269 risk of gonococcal salpingitis. *J Clin Invest* 1994;93:1748-1755.
16
17
18 270 14. Ram S, Cullinane M, Blom AM, et al. Binding of C4b-binding protein to porin: a molecular mechanism of
19
20
21 271 serum resistance of *Neisseria gonorrhoeae*. *J Exp Med* 2001;193:281-296.
22
23
24 272 15. Dillard JP, Seifert HS . A variable genetic island specific for *Neisseria gonorrhoeae* is involved in providing
25
26 273 DNA for natural transformation and is found more often in disseminated infection isolates. *Mol Micro*
27
28 274 2001;41:263-277.
29
30
31 275 16. Tapsall J, Phillips E, Shultz T, et al. Strain characteristics and antibiotic susceptibility of isolates of *Neisseria*
32
33
34 276 *gonorrhoeae* causing disseminated gonococcal infection in Australia. *Int J STD & AIDS* 1992;3:273-277.
35
36
37 277 17. Power PM, Ku SC, Rutter K, et al. The phase-variable allele of the pilus glycosylation gene *pglA* is not
38
39 278 strongly associated with strains of *Neisseria gonorrhoeae* isolated from patients with disseminated gonococcal
40
41
42 279 infection. *Infect Immun* 2007;75:3202-3204.
43
44
45 280 18. National Notifiable Diseases Surveillance System. Australian Government Department of Health.
46
47 281 <http://www9.health.gov.au/cda/source/cda-index.cfm>. Accessed 16 July 2019
48
49
50 282 19. Martin IMC, Ison CA, Aanensen DM, et al. Rapid sequence-based identification of gonococcal transmission
51
52
53 283 clusters in a large metropolitan area. *J Infect Dis* 2004;189:1497-1505.
54
55
56
57
58
59
60

- 1
2 284 20. Van Der Ley P, Heckels JE, Virji M, Hoogerhout P, Poolman J . Topology of outer membrane porins in
3
4 285 pathogenic *Neisseria* spp. *Infect Immun* 1991;59:2963-2971.
5
6
7 286 21. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. *Nucleic Acids Res*
8
9 287 2004;32:1792-1797.
10
11
12
13 288 22. Stamatakis A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies.
14
15 289 *Bioinformatics* 2014;30:1312-1313.
16
17
18 290 23. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics*
19
20 291 2014;30:2114-2120.
21
22
23
24 292 24. Bankevich A, Nurk S, Antipov D, et al. SPAdes: a new genome assembly algorithm and its applications to
25
26 293 single-cell sequencing. *J Comput Biol* 2012;19:455-477.
27
28
29 294 25. Harrison OB, Cehovin A, Skett J, et al. *Neisseria gonorrhoeae* population genomics: Use of the gonococcal
30
31 295 core genome to improve surveillance of antimicrobial resistance. *J Infect Dis* 2020;222:1816-1825.
32
33
34
35 296 26. Maiden MCJ, Bygraves JA, Feil E, et al. Multilocus sequence typing: A portable approach to the
36
37 297 identification of clones within populations of pathogenic microorganisms. *Proc Natl Acad Sci U S A*
38
39 298 1998;95:3140-3145.
40
41
42 299 27. Birrell JM, Gunathilake M, Singleton S, et al. Characteristics and impact of disseminated gonococcal
43
44 300 infection in the 'Top End' of Australia. *Am J Trop Med Hyg* 2019;101:753-760.
45
46
47
48 301 28. Jolley KA, Maiden MC. BIGSdb: scalable analysis of bacterial genome variation at the population level. *BMC*
49
50 302 *Bioinformatics* 2010;11:595.
51
52
53 303 29. Letunic I, Bork P .Interactive tree of life (iTOL) v3: an online tool for the display and annotation of
54
55 304 phylogenetic and other trees. *Nuc Acids Res* 2016;44: 242-245.
56
57
58
59
60

1
2 305
3
4
5 306
6
7
8 307
9
10



11
12 308 **Figure Legend**

13
14 309
15

16 310 Figure 1: Core genome maximum likelihood phylogeny of 16 PIA strains of *N. gonorrhoeae* from Queensland
17
18 311 based on cgMLST. The tree is annotated with strain ID, NG-MAST associated with DGI, and sequence types
19
20 312 derived from MLST and NG-MAST, with presence/absence of phase variable *pglA* and gonococcal genetic
21
22 313 island. Visualised with iTOL [29]. Created by the authors.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Tree scale: 0.0001



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	3
Methods			
Study design	4	Present key elements of study design early in the paper	4-5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	4
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4
Bias	9	Describe any efforts to address potential sources of bias	6, 12
Study size	10	Explain how the study size was arrived at	4
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5,6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	5
		(b) Describe any methods used to examine subgroups and interactions	5
		(c) Explain how missing data were addressed	NA
		(d) If applicable, describe analytical methods taking account of sampling strategy	NA
		(e) Describe any sensitivity analyses	NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	4
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	4
		(b) Indicate number of participants with missing data for each variable of interest	4
Outcome data	15*	Report numbers of outcome events or summary measures	8-11
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make	6,8,10,11

		clear which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	10
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	10
Discussion			
Key results	18	Summarise key results with reference to study objectives	12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12
Generalisability	21	Discuss the generalisability (external validity) of the study results	12
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Molecular characterisation of *Neisseria gonorrhoeae* associated with disseminated gonococcal infections in Queensland, Australia

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-061040.R1
Article Type:	Original research
Date Submitted by the Author:	26-May-2022
Complete List of Authors:	Guglielmino, Christine; Health Support Queensland Forensic and Scientific Services Sandhu, Sumeet; Health Support Queensland Forensic and Scientific Services Lau, Colleen L.; Australian National University Research School of Population Health Buckely, Cameron; UQ Centre for Clinical Research, University of Queensland Trembizki, Ella; UQ Centre for Clinical Research, University of Queensland Whiley, David; UQ Centre for Clinical Research, University of Queensland Jennison, Amy; Health Support Queensland Forensic and Scientific Services
Primary Subject Heading:	Sexual health
Secondary Subject Heading:	Public health, Infectious diseases, Epidemiology
Keywords:	Epidemiology < TROPICAL MEDICINE, INFECTIOUS DISEASES, MOLECULAR BIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1 **Molecular characterisation of *Neisseria gonorrhoeae* associated with disseminated gonococcal infections in**
2 **Queensland, Australia**

3 Running Title: DGI and *porB* genotype

4 Christine J. D. Guglielmino¹, Sumeet Sandhu¹, Colleen L. Lau^{2,3}, Cameron Buckley⁴, Ella Trembizki⁴, David M.
5 Whiley⁴, Amy V. Jennison^{1*}

6 ¹Public Health Microbiology, Queensland Health Forensic and Scientific Services, Brisbane, Australia

7 ²Research School of Population Health, Australian National University, Canberra, Australia

8 ³School of Public Health, University of Queensland, Brisbane, Australia

9 ⁴UQ Centre for Clinical Research, University of Queensland, Brisbane, Australia

10 *Corresponding Author: Amy.Jennison@health.qld.gov.au PO Box 594, Archerfield, Queensland 4108,
11 Australia. Telephone: +61730962821 fax: +61730962973

12 **Abstract word count:227**

13 **Text word count: 2113**

21 **ABSTRACT**

1
2
3 22 **Objectives:** Gonorrhoea caused by *Neisseria gonorrhoeae* is the second most notified sexually transmitted
4
5
6 23 infection in Australia and case numbers for this STI have been increasing globally. Progressive gonococcal
7
8 24 infection may lead to Disseminated gonococcal infection (DGI) which causes significant morbidity among
9
10 25 patients. This study aimed to examine the genetic diversity of *N. gonorrhoeae* isolates collected in Queensland
11
12 26 from January 2010 to August 2015 and to determine factors associated with DGI in Queensland.
13
14

15 27 **Design:** Retrospective surveillance study for epidemiological purposes.
16
17

18
19 28 **Setting:** All gonorrhoeae isolates referred by private and public pathology laboratories to the state of
20
21 29 Queensland, Australia Neisseria reference laboratory.
22
23

24 30 **Methods:** Between January 2010 and August 2015, 3953 *Neisseria gonorrhoeae* isolates from both
25
26 31 metropolitan and regional Queensland infections were typed with NG-MAST (*N. gonorrhoeae* multi antigen
27
28 32 sequence typing) to assess the genetic diversity between strains. Whole genome sequencing (WGS) was used
29
30 33 to investigate strain related factors associated with DGI.
31
32
33

34 34 **Results:** ST6876 was the most common NG-MAST type, detected in 7.6% of the isolates. DGI was significantly
35
36 35 more likely in females <30 years (OR 13.02, $p<0.0001$) and in older males >30 years (OR 6.04, $p<0.0001$), with
37
38 36 most cases originating from North Queensland (OR 8.5, $p<0.0001$). Strains harbouring PIA class of *porB* type
39
40 37 were associated with DGI (OR 33.23, $p<0.0001$).
41
42
43

44 38 **Conclusion:** Genotyping techniques such as NG-MAST and WGS are proving instrumental in providing an insight
45
46 39 into the population structure of *N. gonorrhoeae*, and genetic mechanisms of pathogenesis, such as for DGI.
47
48
49

50 40 **Keywords:** *Neisseria gonorrhoeae*; Gonorrhoea; DGI; Australia; Genotype; NG-MAST; WGS
51
52
53 41
54
55
56 42
57
58
59
60

Strengths and Limitations of this study

- Genetic diversity of over 3500 *N. gonorrhoeae* isolates were assessed by NG-MAST genotyping.
- Demographic factors associated with NG infection and DGI cases were examined across all isolates.
- Genotyping assisted in identification of populations associated with higher incidence of DGI.
- Only a small number of strains were further characterised by whole genome sequencing, meaning significance of associations with genetic markers such as *pglA*, PIA *porB* type and gonococcal genetic island could not be drawn and further studies with larger rates of whole genome sequencing are needed to address this.

INTRODUCTION

Disseminated gonococcal infection (DGI) is a complication of gonorrhoea from bacteraemic spread of *Neisseria gonorrhoeae*. It typically presents as an arthritis-dermatitis syndrome but in rare cases can lead to death via septic shock [1]. DGI primarily occurs in individuals with an asymptomatic untreated primary infection, most often female, although some studies have shown an association with males [2-4]. Early diagnosis and treatment are required to avert significant morbidity.

Both host and *N. gonorrhoeae* strain-related factors can predispose to DGI. Host associated risk factors include recent menstruation, pregnancy and complement deficiencies [5-7]. Several strain-related factors have been proposed including exhibiting an arginine-hypoxanthine-uracil (AHU) auxotype, expressing particular phase-variable variants of the pilus glycosyl transferase A (*pgtA*) gene, opacity genes, and harbouring a PIA class of *porB* gene (as opposed to PIB) [8-14]. Gonococcal genetic island (GGI) is another speculated virulence factor encoding a Type IV secretion system (T4SS) which plays a role in horizontal gene transfer [15]. However, except for the PIA gene, evidence to support the strain-related factors is limited. For example, an early study of DGI-causing gonococci in Australia found that none were of the AHU auxotype, while a later Australian study found no strong association with the phase-variable allele of the *pglA* gene, subsequently referred to as the *pglA* gene [16,17]. Previous studies assessing stain-related factors associated with DGI are limited by sample size and/or lack of comparison to non-DGI isolates.

69 We sought to assess the genetic diversity of *N. gonorrhoeae* isolates collected in Queensland from January
1
2 70 2010 to August 2015 and to determine factors associated with DGI in Queensland. In addition, we utilised WGS
3
4 71 to gain insight to any existing strain-related factors which may have contributed to the occurrence of DGI.
5
6
7

8 72 **METHODS**

11 73 ***N. gonorrhoeae* isolates from Queensland**

14 74 From 2010 to 2015, the Australian state of Queensland reported 16,506 gonococcal infections over the 6 years,
15
16 75 equivalent to an average notification rate of 60 cases per 100,000 population per year [18]. Approximately 75%
17
18 76 of these notifications were diagnosed by NAAT only, with no isolate available for further testing. Diagnostic
19
20 77 methods used varied across the state, with 80% of cases in the northern Queensland regions diagnosed by
21
22 78 NAAT only, as opposed to 70% of cases from the rest of the state; with larger variations of between 58% and to
23
24 79 84% for individual health service districts. A total of 3953 *N. gonorrhoeae* isolates were included in this study,
25
26 80 isolated from specimens collected between January 2010 and August 2015 in pathology laboratories servicing
27
28 81 Queensland and surrounding areas and subsequently referred to the state reference laboratory at Queensland
29
30 82 Health Forensic and Scientific Services. One isolate per patient episode, defined as not collected within one
31
32 83 month of a previously included strain, was included. Data collected for each isolate included date of specimen
33
34 84 collection, age, sex, postcode of residence and specimen type. To identify disease prevalence in specific age
35
36 85 groups isolates from males and females were grouped into two groups, <30 years and ≥30 years. Postcode of
37
38 86 residence was used to assign broad geographic region categories of NQ (northern Queensland) and SEQ (south-
39
40 87 east Queensland) and other (sparsely populated central Queensland, interstate, or overseas). DGI was defined
41
42 88 where the organism was isolated from blood culture, joint fluid and/or tissue.
43
44
45
46
47
48

49 89 **NG-MAST typing and Phylogenetic analysis**

52 90 Crude DNA extracts of all the *N. gonorrhoeae* isolates received in the study period were routinely subjected to
53
54 91 *N. gonorrhoeae* multi-antigen sequence typing (NG-MAST) as previously described [19]. These extracts were
55
56 92 prepared by boiling 400µL of TE buffer containing a loopful (1µL) of pure *N. gonorrhoeae* colonies at 100°C for
57
58
59

10 minutes. NG-MAST comprises DNA sequencing of partial *tbpB* and *porB* genes and subsequent analysis via an online database to assign allele and sequence types (www.ng-mast.net). The *porB* sequence data from the NG-MAST was analysed to assign either PIA or PIB class [20]. The analysis was based on a phylogenetic assessment, and comparison with previously recognised PIA and PIB sequences from GenBank.

WGS and Bioinformatic analysis

To investigate strain-related factors associated with DGI, we selected 16 isolates from 8 different NG-MAST types which were prevalent in DGI, in this study. Two strains from each NG-MAST were selected, comprising both DGI and non-DGI strains. DNA was extracted from isolates using the QIA Symphony SP, using the DSP DNA minikit (Qiagen, Germany), as per manufacturer's guidelines. WGS was performed on the Illumina NextSeq 500 platform (Illumina, CA, USA) using NextSeq 500 Mid Output V2 kit (Illumina) with Nextera XT library preparation. Reads were trimmed with Trimmomatic (Version 0.36) [21], corrected and assembled with Spades (Version 3.10.1) (<https://github.com/ablab/spades>) [22], and assemblies uploaded to pubMLST to determine presence/absence of the gonococcal genetic island [23], and analysed with Ridom SeqSphere+ 4.1.0 (Ridom GmbH, Germany) using alleles from 1,649 *N. gonorrhoeae* cgMLST v1.0 loci [24], and *Neisseria* spp. MLST [25]. WGS assemblies are available on pubMLST with ID numbers 52753-52768. WGS raw sequence files and associated metadata have been submitted to the European Nucleotide Archive with Project Accession number PRJEB52601.

Statistical Analysis

Descriptive analysis was performed using Microsoft Excel. Annual rates of reported cases were computed by using the number of cases reported as numerators, and statistics Queensland yearly population as denominators. Categorical variables were examined using the Fischer's Exact test performed in GraphPad Prism 7 (GraphPad Software Inc., California). Odds ratios (OR) with 95% confidence intervals were obtained from logistic regression models in Microsoft Excel to quantify associations between independent variables and outcome. P values of <0.05 were considered statistically significant.

117 **Patient and Public Involvement**

118 No patients involved.

119 **RESULTS**120 **Demographics and *N. gonorrhoeae* isolates**

121 The total 3,953 *N. gonorrhoeae* isolates in this study from January 2010 to August 2015 consisted of genital
 122 (n=3,099; 78.3%), invasive (n=64; 1.6%), anorectal (n=456; 11.5%), oropharyngeal (n=233; 5.8%), ocular (n=31;
 123 0.7%), and other/not specified (n=70; 1.7%) specimen types, as listed in Supplementary Data Table 1. Overall,
 124 majority of these isolates were reported in SEQ (n= 2403; 60.7%), followed by NQ (n=1193; 30.1%) and other
 125 regions (sparsely populated central Queensland, interstate, or overseas) which constituted of 9% (n=357) of
 126 the total cases. The isolates comprised 73% (n=2898) from males (62.9 cases per 100,000 population) and 27%
 127 (n=1055) from females (22.9 cases per 100,000 population). Further breakdown into age groups showed that
 128 20.4% (n=808) gonococcal infections were represented by females <30 years of age and 5.9% of infections
 129 were reported in females ≥30 years of age. Similar trend was observed in males where 44.3% (n=1754) of *N.*
 130 *gonorrhoeae* infections were noted in males <30 year of age and 28.3% (n=1119) of infections were present in
 131 males ≥30 years of age. PIB class of porB was assigned to 72.7% (n=2875) of isolates whereas 27.3% (n=1078)
 132 of the isolates belonged to porB class PIA. Table 1 shows a breakdown for all strains by PIA/PIB, NQ/SEQ, and
 133 age group.

134 **Table 1: Demographics of *N. gonorrhoeae* isolates, Queensland January 2010 to August 2015. Created by the**
 135 **authors.**

Demographics		n	Percentage (%) of total
All cases		3953	100
porB Class	PIA	1078	27.3
	PIB	2875	72.7

Geographic location	NQ	1193	30.1
	SEQ	2403	60.7
	Others	357	9.0
Sex	F	1055	26.6
	M	2898	73.3
Age groups	<30 Female	808	20.4
	≥30 Female	234	5.9
	<30 Male	1754	44.3
	≥30 Male	1119	28.3
	Age not specified	38	0.9

NG-MAST typing and Phylogenetic analysis

Among the 3,953 isolates tested, 574 alleles of *porB* gene were identified, the most prevalent of which was the 4101 allele, present in 441 isolates (11.1%). The *tbpB* gene was represented by 250 alleles with the most frequent allele was 29, detected in 653 isolates (16.5%). Combinations of *porB* and *tbpB* alleles resulted in 823 NG-MAST types. Overall ST6876 was the most common NG-MAST type, detected in 302 isolates (7.6%). It was also the most prevalent in years 2010 and 2011, represented by 126 (16.1%) and 109 (14.4%) isolates, respectively. In 2012 and 2013, ST21 became more prevalent, represented by 8.6% and 6.0% of the isolates collected in those years. In 2014 and 2015 (up to August), ST4186 was found with high frequency with 7.1% and 10.1% of the isolates, respectively. 771 STs were represented by only one isolate, and these STs accounted for between 16.8% and 23.3% of total isolates each year. Table 2 shows a summary of the most frequent alleles and types over the five years.

150
1
2
3 151
4
5
6
7 152
8
9
10 153
11
12
13 154
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

155 **Table 2: NG-MAST typing of isolates collected in Queensland from January 2010 to August 2015. Created by the authors.**

Year	Number of <i>N. gonorrhoeae</i> isolates	Number of <i>porB</i> alleles	Most frequent <i>porB</i> alleles	Number of <i>tbpB</i> alleles	Most frequent <i>tbpB</i> alleles	Number of NG-MAST types	Most frequent NG-MAST types	<i>porB</i> Class	Invasive (DGI) isolates *
2010	782	165	porB 4101 (18.7%)	87	tbpB 29 (17.6%)	208	6876 (16.1%)	PIA - 255 (32.6%) PIB - 527 (67.3%)	12 (1.5%)
			porB 2280 (5.3%)		tbpB 1330 (16.3%)		6863 (5.4%)		
			porB 908 (4.7%)		tbpB 1329 (8.4%)		1407 (4.7%)		
			porB 1808 (4.4%)		tbpB 110 (6.6%)		2992 (4.4%)		
			porB 4143 (3.7%)		tbpB 349 (6.1%)		6940 (3.7%)		
2011	754	157	porB 4101 (17.9%)	85	tbpB 29 (24.0%)	206	6876 (14.4%)	PIA - 240 (31.8%) PIB - 514 (68.1%)	8 (1.0%)
			porB 1808 (8.8%)		tbpB 1330 (15.5%)		2992 (8.8%)		
			porB 4099 (5.3%)		tbpB 349 (7.0%)		6879 (4.7%)		
			porB 14 (4.7%)		tbpB 33 (6.7%)		21 (4.4%)		
			porB 4104 (3.7%)		tbpB 1329 (6.1%)		6937 (3.2%)		
2012	680	156	porB 4101 (12.2%)	91	tbpB 29 (19.7%)	203	21 (8.6%)	PIA - 195 (28.6%) PIB - 485 (71.3%)	10 (1.4%)
			porB 14 (8.6%)		tbpB 349 (12.3%)		2992 (7.6%)		
			porB 4099 (7.7%)		tbpB 33 (10.8%)		6879 (7.5%)		
			porB 1808 (7.6%)		tbpB 1330 (9.1%)		6876 (7.0%)		
			porB 4104 (5.5%)		tbpB 1329 (7.0%)		6937 (4.1%)		
2013	650	167	porB 1808 (7.2%)	93	tbpB 29 (18.9%)	217	21 (6.0%)	PIA - 160 (24.6%) PIB - 490 (75.3%)	10 (1.5%)
			porB 4101 (6.7%)		tbpB 349 (8.3%)		4822 (6.0%)		
			porB 1903 (6.1%)		tbpB 33 (7.5%)		6879 (5.3%)		
			porB 14 (6.0%)		tbpB 110 (6.9%)		4186 (5.2%)		
			porB 4099 (5.3%)		tbpB 241 (6.9%)		5533 (4.0%)		
2014	633	147	porB 1808 (14.6%)	90	tbpB 241 (8.5%)	201	4186 (7.1%)	PIA - 140 (22.1%) PIB - 493 (77.8%)	18 (2.8%)
			porB 2569 (7.2%)		tbpB 29 (7.8%)		9654 (5.6%)		
			porB 147 (6.4%)		tbpB 4 (7.1%)		4244 (4.8%)		
			porB 4101 (4.5%)		tbpB 110 (6.1%)		10039 (3.7%)		
			porB 5912 (3.7%)		tbpB 1744 (6.0%)		5004 (2.3%)		
2015**	454	115	porB 1808 (12.1%)	74	tbpB 241 (16.5%)	154	4186 (10.1%)	PIA - 87 (19.1%) PIB - 367 (80.8%)	6 (1.3%)
			porB 2569 (10.1%)		tbpB 4 (6.4%)		4244 (5.2%)		
			porB 147 (8.14%)		tbpB 29 (5.9%)		9654 (4.4%)		
			porB 2656 (5.0%)		tbpB 893 (5.7%)		9909 (3.9%)		
			porB 543(4.1%)		tbpB 1744 (5.3%)		11821 (3.7%)		

156 *percentage of total isolates

157 **Data Collected up until August 2015

158

Disseminated Gonococcal Infection

From January 2010 to August 2015, 64 DGI-related isolates were received by the reference laboratory, comprising 1.6% of total isolates; 49 cases (76.6%) were diagnosed from joint samples and 15 (23.4%) from blood samples. This study only had access to cultured gonococcal isolates, so any DGI cases diagnosed by NAAT only are not considered here. A summary of the demographics, *porB* class types and strain types (n=8) associated with DGI cases is provided in Table 3. Even though the majority of total gonococcal isolates were from males, DGI was significantly more likely in females (OR 4.72, $p<0.0001$), particularly in those aged <30 years (OR 13.02, $p<0.0001$) and in older males aged >30 years (OR 6.04, $p<0.0001$) when compared to their younger counterparts. The majority of DGI cases (n=50; 78%) originated from the north Queensland, and cases from this region had higher odds of being associated with DGI (OR 8.5, $p<0.0001$). A total of 31 STs of the total 823 were observed amongst the 64 DGI cases. PIA *porB* type was significantly associated with DGI (OR 33.23, $p<0.0001$), and accounted for 59 (92.2%) of the 64 DGI cases. Seven of the prevalent NG-MASTs in DGI (ST758, ST6886, ST6937, ST6939, ST7126, ST8712, and ST10711), all with PIA class of *porB*, were found to be individually associated with DGI (Table 3). However, the most prevalent NG-MAST in this study ST6876 (n=302), which is also PIA class of *porB*, was not found to be associated with DGI (n=6) (OR 1.2, $p=0.6$).

Table 3: Demographic factors, *porB* type and NG-MAST types associated with disseminated gonococcal infection (DGI) in Queensland (January 2010 to August 2015). Created by the authors.

Risk factor		Non-DGI	DGI	Total	DGI as percentage (%)	Univariate OR	p value
porB class	PIA	1019	59	1078	5.5	33.23	<0.0001
	PIB	2870	5	2875	0.2	0.03	
Geographic location	NQ	1143	50	1193	4.2	8.5	<0.0001
	SEQ	2394	9	2403	0.4	0.1	
	Other	352	5	357	1.4	0.85	
Sex	Female	1015	40	1055	3.8	4.72	<0.0001
	Male	2874	24	2898	0.8	0.2	
Age group (years)	<30 Female	779	29	808	3.58	13.02	<0.0001
	<30 Male	1749	5	1754	0.2	0.07	
	≥30 Female	223	11	234	4.7	2.85	0.01
	≥30 Male	1100	19	1119	1.69	0.35	
	<30 Female	779	29	808	3.58	0.75	0.44
	≥30 Female	223	11	234	4.7	1.32	
	<30 Male	1749	5	1754	0.2	0.16	<0.0001
	≥30 Male	1100	19	1119	1.69	6.04	
	Age not specified	38	0	38	0.0		
Prevalent NG-MAST	ST758	17	2	19	10.5	3.67	0.03
	ST6876	296	6	302	2.0	1.2	0.6

types	ST6886	30	3	33	9.1	6.3	0.001
	ST6937	80	14	94	14.9	13.3	<0.0001
	ST6939	34	3	37	8.1	5.57	0.02
	ST7126	22	3	25	12.0	8.6	0.007
	ST8712	17	5	22	22.7	19.3	<0.0001
	ST10711	15	3	18	16.7	12.7	0.002
	Other STs	3378	25	3403	0.7	0.09	
	Total	3889	64	3953	1.6%		

Whole Genome Sequencing

Figure 1 shows a core genome phylogeny of the 16 strains from 8 different NG-MAST, all of which were PIA types, selected for WGS. The four ST6886 and ST6937 strains contained phase variable *pglA* (NEIS0213) alleles with long homopolymeric tracts of Gs, while the others did not. These four strains grouped together by cgMLST, despite one of them sharing an MLST profile with other strains that did not form part of this group. Only one of the 16 strains sequenced did not possess the gonococcal genetic island.

DISCUSSION

This study investigated the burden of gonococcal infections in Queensland and identified those most at risk of developing DGI. The increasing gonorrhoea rates among males could be a result of rapidly increasing rates of gonorrhoea in the MSM population. Another explanation would be that gonorrhoea is more symptomatic in men and as a result they are more likely to seek health care. In this study, we applied *N. gonorrhoeae* NG-MAST genotyping to a large, diverse, consecutively collected *N. gonorrhoeae* isolate collection in a setting where DGI is not uncommon and used WGS to investigate other strain-related factors. We have used a dataset of strains that encompassed both metropolitan and regional populations and has subsequently highlighted different populations vulnerable to DGI. We observed a higher likelihood of DGI in females, in cases reported in NQ

1
2 197 when compared to SEQ, and with strains harbouring the PIA gene. This finding agrees with previous studies
3
4 198 suggesting female predominance [2] but contradicts a more recent study from the Northern Territory of
5
6 199 Australia which did not show any significant association between DGI and sex [26], but did not examine strain-
7
8
9 200 related factors such as PIA/PIB. Moreover, our data may indicate that DGI is associated with certain PIA gene
10
11 201 positive NG-MAST types, suggesting that additional mechanisms possessed by particular PIA bearing genotypes
12
13 202 may be at play. PIA has previously been reported to be associated with DGI due to a diminished inflammatory
14
15 203 response, which increases the chances that a mucosal infection may go untreated and therefore progress to
16
17
18 204 DGI [12].

19
20
21 205 Our data identified *pglA* phase variation present within certain NG-MAST types that were associated with DGI,
22
23 206 however further studies with larger diversity of strain collections are required, as this finding is inconsistent
24
25 207 with the work of Power *et al* [17]. Our sequencing work did not show any evidence that DGI is associated with
26
27
28 208 the gonococcal genetic island as seen by Dillard *et al* [15], however with the limited number of strains we
29
30 209 sequenced, no statistical significance can be drawn and further studies are required to confirm or refute this.
31
32 210 Data on the co-existence of genital infections for DGI cases was not consistently available, however there were
33
34 211 DGI cases that did not have a genital infection recorded in the dataset. Absence of a genital infection suggests
35
36
37 212 cases may have cleared a mucosal infection before progressing to DGI, which would be more likely for
38
39 213 asymptomatic infections in females rather than via anorectal injury infection in males.

40
41
42 214 The majority of gonorrhoea cases yielding an isolate are represented by males who continue to have higher
43
44 215 notification rates than females in Queensland. DGI is not a rare occurrence, being noted in 1.6% of culture-
45
46 216 positive cases, and younger females showing higher rates than males. High DGI rates among younger women
47
48
49 217 are concerning as infertility is one of the potential outcomes of untreated gonorrhoea infection, which has
50
51 218 downstream social and economic impacts. Genotyping techniques such as NG-MAST and WGS are proving
52
53 219 instrumental in providing an insight into the population structure of *N. gonorrhoeae*, and genetic mechanisms
54
55 220 of pathogenesis, such as for DGI.

1
2 221 **Contributorship statement**
3
4

5 222 Amy Jennison and David Whiley conceptualised the study. Christine Guglielmino conducted the laboratory
6
7 223 investigation. Christine Guglielmino, Sumeet Sandhu, Colleen Lau, Cameron Buckley and Ella Trembizki
8
9
10 224 performed formal data analysis. All authors contributed to the writing and review of the manuscript.
11
12

13 225 **Acknowledgments**
14
15

16 226 This publication made use of the Neisseria Multi Locus Sequence Typing website ([https://pubmlst.org/](https://pubmlst.org/neisseria/)
17
18 227 [neisseria/](https://pubmlst.org/neisseria/)) developed by Keith Jolley and sited at the University of Oxford [23]. The development of this site
19
20 228 has been funded by the Wellcome Trust and European Union. We thank all laboratories for referring isolates
21
22
23 229 included in this study, and Public Health Microbiology Staff for technical work.
24
25

26 230 **Conflicts of interest. None**
27
28

29 231 **Data Availability**
30
31

32 232 WGS raw sequence files and associated metadata have been submitted to the European Nucleotide Archive
33
34
35 233 with Project Accession number PRJEB52601.
36
37

38 234 **Funding:** This research did not receive any specific grant from funding agencies in the public, commercial, or
39
40 235 not-for-profit sectors.
41
42

43 236 **Corresponding Author:** Amy.Jennison@health.qld.gov.au PO Box 594, Archerfield, Queensland 4108, Australia.

44
45
46 237 Telephone: +61730962821 fax: +61730962973
47
48

49 238 **Transparency declarations:** D.M.W. reports research funding from SpeeDx Pty Ltd and is supported by a
50
51 239 Queensland Advancing Clinical Research Fellowship from the Queensland Government. E.T is holding an
52
53 240 NHMRC Early Career Fellowship. CLL is supported by an NHMRC Investigator Grant (APP1193826).
54
55
56
57
58
59
60

1
2 241 **Ethics Approvals:** The study was approved by Forensic and Scientific Services Human Ethics Committee (FSS-
3
4 242 HEC, EC00305). HEC Ref Number HEC18_01.
5
6

7 243 **REFERENCES**
8
9

- 10 244 1 Thiéry G, Tankovic J, Brun-Buisson C, et al. Gonococemia associated with fatal septic shock. *Clin Infect Dis*
11
12 2001;32:92-93.
13 245
14
15 246 2. Tuttle CS, Van Dantzig T, Brady S, et al. The epidemiology of gonococcal arthritis in an Indigenous Australian
16
17 247 population. *Sex Transm Infect* 2015;91:497-501.
18
19
20 248 3. Suzaki A, Hayashi K, Kosuge K, et al. Disseminated gonococcal infection in Japan: a case report and literature
21
22 249 review. *Inter Med* 2011;50:2039-2043.
23
24
25 250 4. Belkacem A, Caumes E, Ouanich J, et al. Changing patterns of disseminated gonococcal infection in France:
26
27 251 cross-sectional data 2009–2011. *Sex Transm Infect* 2013; 9:613-615.
28
29
30 252 5. Bleich AT, Sheffield JS, Wendel Jr GD, et al. Disseminated gonococcal infection in women. *Obstet Gynecol*
31
32 253 2012;119:597-602.
33
34
35 254 6. Phupong V, Sittisomwong T, Wisawasukmongchol W. Disseminated gonococcal infection during pregnancy.
36
37 255 *Gynecol and Obstet* 2005;273:185-186.
38
39
40 256 7. Petersen BH, Lee TJ, Snyderman R, et al. *Neisseria meningitidis* and *Neisseria gonorrhoeae* bacteremia
41
42 257 associated with C6, C7, or C8 deficiency. *Annals Int Med* 1979;90:917-920.
43
44
45 258 8. Banerjee A, Wang R, Supernavage SL, et al. Implications of phase variation of a gene (*pgtA*) encoding a pilin
46
47 259 galactosyl transferase in gonococcal pathogenesis. *J of Exp Med* 2002;196 (2):147-162.
48
49
50 260 9. Roth A, Mattheis C, Muenzner P, et al. Innate recognition by neutrophil granulocytes differs between
51
52 261 *Neisseria gonorrhoeae* strains causing local or disseminating infections. *Infect Immun* 2013;81:2358-2370.
53
54
55
56
57
58
59
60

- 1
2 262 10. Knapp JS, Holmes KK. Disseminated gonococcal infections caused by *Neisseria gonorrhoeae* with unique
3
4 263 nutritional requirements. *J Infect Dis* 1975;132:204-208.
5
6
7 264 11. Brunham RC, Plummer F, Slaney L, et al. Correlation of auxotype and protein I type with expression of
8
9
10 265 disease due to *Neisseria gonorrhoeae*. *J Infect Dis* 1985;152:339-343.
11
12
13 266 12. van Putten JP, Duensing TD, Carlson J. Gonococcal invasion of epithelial cells driven by P. IA, a bacterial ion
14
15 267 channel with GTP binding properties. *J Exp Med* 1998;188:941-952.
16
17
18 268 13. Plummer FA, Chubb H, Simonsen JN, et al. Antibodies to opacity proteins (Opa) correlate with a reduced
19
20
21 269 risk of gonococcal salpingitis. *J Clin Invest* 1994;93:1748-1755.
22
23
24 270 14. Ram S, Cullinane M, Blom AM, et al. Binding of C4b-binding protein to porin: a molecular mechanism of
25
26 271 serum resistance of *Neisseria gonorrhoeae*. *J Exp Med* 2001;193:281-296.
27
28
29 272 15. Dillard JP, Seifert HS . A variable genetic island specific for *Neisseria gonorrhoeae* is involved in providing
30
31
32 273 DNA for natural transformation and is found more often in disseminated infection isolates. *Mol Micro*
33
34 274 2001;41:263-277.
35
36
37 275 16. Tapsall J, Phillips E, Shultz T, et al. Strain characteristics and antibiotic susceptibility of isolates of *Neisseria*
38
39 276 *gonorrhoeae* causing disseminated gonococcal infection in Australia. *Int J STD & AIDS* 1992;3:273-277.
40
41
42 277 17. Power PM, Ku SC, Rutter K, et al. The phase-variable allele of the pilus glycosylation gene *pgIA* is not
43
44
45 278 strongly associated with strains of *Neisseria gonorrhoeae* isolated from patients with disseminated gonococcal
46
47 279 infection. *Infect Immun* 2007;75:3202-3204.
48
49
50 280 18. National Notifiable Diseases Surveillance System. Australian Government Department of Health.
51
52 281 <http://www9.health.gov.au/cda/source/cda-index.cfm>. Accessed 16 July 2019
53
54
55
56
57
58
59
60

- 1
2 282 19. Martin IMC, Ison CA, Aanensen DM, et al. Rapid sequence-based identification of gonococcal transmission
3
4 283 clusters in a large metropolitan area. *J Infect Dis* 2004;189:1497-1505.
5
6
7 284 20. Van Der Ley P, Heckels JE, Virji M, Hoogerhout P, Poolman J . Topology of outer membrane porins in
8
9
10 285 pathogenic *Neisseria* spp. *Infect Immun* 1991;59:2963-2971.
11
12
13 286 21. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics*
14
15 287 2014;30:2114-2120.
16
17
18 288 22. Bankevich A, Nurk S, Antipov D, et al. SPAdes: a new genome assembly algorithm and its applications to
19
20 289 single-cell sequencing. *J Comput Biol* 2012;19:455-477.
21
22
23
24 290 23. Jolley KA, Maiden MC. BIGSdb: scalable analysis of bacterial genome variation at the population level. *BMC*
25
26 291 *Bioinformatics* 2010;11:595.
27
28
29 292 24. Harrison OB, Cehovin A, Skett J, et al. *Neisseria gonorrhoeae* population genomics: Use of the gonococcal
30
31 293 core genome to improve surveillance of antimicrobial resistance. *J Infect Dis* 2020;222:1816-1825.
32
33
34
35 294 25. Maiden MCJ, Bygraves JA, Feil E, et al. Multilocus sequence typing: A portable approach to the
36
37 295 identification of clones within populations of pathogenic microorganisms. *Proc Natl Acad Sci U S A*
38
39 296 1998;95:3140-3145.
40
41
42 297 26. Birrell JM, Gunathilake M, Singleton S, et al. Characteristics and impact of disseminated gonococcal
43
44 298 infection in the 'Top End' of Australia. *Am J Trop Med Hyg* 2019;101:753-760.
45
46
47
48 299 27. Letunic I, Bork P .Interactive tree of life (iTOL) v3: an online tool for the display and annotation of
49
50 300 phylogenetic and other trees. *Nuc Acids Res* 2016;44: 242-245.
51
52
53 301
54
55
56
57 302
58
59
60



1
2 303 **Figure Legend**

3
4 304

5
6 305 Figure 1: Core genome maximum likelihood phylogeny of 16 PIA strains of *N. gonorrhoeae* from Queensland
7
8 306 based on cgMLST. The tree is rooted at centre-point and annotated with strain ID, NG-MAST associated with
9
10 307 DGI, and sequence types derived from MLST and NG-MAST, with presence/absence of phase variable *pglA* and
11
12 308 gonococcal genetic island. The phylogenetic distance is indicated by the length of the horizontal lines.
13
14
15 309 Visualised with iTOL [27]. Created by the authors.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Tree scale: 0.0001



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	3
Methods			
Study design	4	Present key elements of study design early in the paper	4-5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	4
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4
Bias	9	Describe any efforts to address potential sources of bias	6, 12
Study size	10	Explain how the study size was arrived at	4
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5,6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	5
		(b) Describe any methods used to examine subgroups and interactions	5
		(c) Explain how missing data were addressed	NA
		(d) If applicable, describe analytical methods taking account of sampling strategy	NA
		(e) Describe any sensitivity analyses	NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	4
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	4
		(b) Indicate number of participants with missing data for each variable of interest	4
Outcome data	15*	Report numbers of outcome events or summary measures	8-11
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make	6,8,10,11

		clear which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	10
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	10
Discussion			
Key results	18	Summarise key results with reference to study objectives	12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12
Generalisability	21	Discuss the generalisability (external validity) of the study results	12
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Molecular characterisation of *Neisseria gonorrhoeae* associated with disseminated gonococcal infections in Queensland, Australia: a retrospective surveillance study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-061040.R2
Article Type:	Original research
Date Submitted by the Author:	30-Jun-2022
Complete List of Authors:	Guglielmino, Christine; Health Support Queensland Forensic and Scientific Services Sandhu, Sumeet; Health Support Queensland Forensic and Scientific Services Lau, Colleen L.; Australian National University Research School of Population Health Buckely, Cameron; UQ Centre for Clinical Research, University of Queensland Trembizki, Ella; UQ Centre for Clinical Research, University of Queensland Whiley, David; UQ Centre for Clinical Research, University of Queensland Jennison, Amy; Health Support Queensland Forensic and Scientific Services
Primary Subject Heading:	Sexual health
Secondary Subject Heading:	Public health, Infectious diseases, Epidemiology
Keywords:	Epidemiology < TROPICAL MEDICINE, INFECTIOUS DISEASES, MOLECULAR BIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1 **Molecular characterisation of *Neisseria gonorrhoeae* associated with disseminated gonococcal infections in**
2 **Queensland, Australia: a retrospective surveillance study**

3 Running Title: DGI and *porB* genotype

4 Christine J. D. Guglielmino¹, Sumeet Sandhu¹, Colleen L. Lau^{2,3}, Cameron Buckley⁴, Ella Trembizki⁴, David M.
5 Whiley⁴, Amy V. Jennison^{1*}

6 ¹Public Health Microbiology, Queensland Health Forensic and Scientific Services, Brisbane, Australia

7 ²Research School of Population Health, Australian National University, Canberra, Australia

8 ³School of Public Health, University of Queensland, Brisbane, Australia

9 ⁴UQ Centre for Clinical Research, University of Queensland, Brisbane, Australia

10 *Correspondence to: Amy V Jennison

11 Amy.Jennison@health.qld.gov.au

12 PO Box 594, Archerfield, Queensland 4108, Australia. Telephone: +61730962821 fax: +61730962973

13 **Abstract word count:227**

14 **Text word count: 2113**

21 **ABSTRACT**

1
2
3 22 **Objectives:** Gonorrhoea caused by *Neisseria gonorrhoeae* is the second most notified sexually transmitted
4
5
6 23 infection in Australia and case numbers for this STI have been increasing globally. Progressive gonococcal
7
8 24 infection may lead to Disseminated gonococcal infection (DGI) which causes significant morbidity among
9
10 25 patients. This study aimed to examine the genetic diversity of *N. gonorrhoeae* isolates collected in Queensland
11
12 26 from January 2010 to August 2015 and to determine factors associated with DGI in Queensland.
13
14

15 27 **Design:** Retrospective surveillance study for epidemiological purposes.
16
17

18
19 28 **Setting:** All gonorrhoeae isolates referred by private and public pathology laboratories to the state of
20
21 29 Queensland, Australia Neisseria reference laboratory.
22
23

24 30 **Methods:** Between January 2010 and August 2015, 3953 *Neisseria gonorrhoeae* isolates from both
25
26 31 metropolitan and regional Queensland infections were typed with NG-MAST (*N. gonorrhoeae* multi antigen
27
28 32 sequence typing) to assess the genetic diversity between strains. Whole genome sequencing (WGS) was used
29
30 33 to investigate strain related factors associated with DGI.
31
32
33

34 34 **Results:** ST6876 was the most common NG-MAST type, detected in 7.6% of the isolates. DGI was significantly
35
36 35 more likely in females <30 years (OR 13.02, $p<0.0001$) and in older males >30 years (OR 6.04, $p<0.0001$), with
37
38 36 most cases originating from North Queensland (OR 8.5, $p<0.0001$). Strains harbouring PIA class of *porB* type
39
40 37 were associated with DGI (OR 33.23, $p<0.0001$).
41
42
43

44 38 **Conclusion:** Genotyping techniques such as NG-MAST and WGS are proving instrumental in providing an insight
45
46 39 into the population structure of *N. gonorrhoeae*, and genetic mechanisms of pathogenesis, such as for DGI.
47
48
49

50 40
51
52
53 41 **Keywords:** Neisseria gonorrhoeae; Gonorrhoea; DGI; Australia; Genotype; NG-MAST; WGS
54
55
56 42

43

44 **Strengths and limitations of this study**

- 45 ▪ Genetic diversity of over 3500 *N. gonorrhoeae* isolates were assessed by NG-MAST genotyping.
- 46 ▪ Demographic factors associated with NG infection and DGI cases were examined across all isolates.
- 47 ▪ Genotyping assisted in identification of populations associated with higher incidence of DGI.
- 48 • Only a small number of strains were further characterised by whole genome sequencing, meaning
49 significance of associations with genetic markers such as *pglA*, PIA *porB* type and gonococcal genetic
50 island could not be drawn and further studies with larger rates of whole genome sequencing are
51 needed to address this.

52

53 **INTRODUCTION**

54 Disseminated gonococcal infection (DGI) is a complication of gonorrhoea from bacteraemic spread of *Neisseria*
55 *gonorrhoeae*. It typically presents as an arthritis-dermatitis syndrome but in rare cases can lead to death via
56 septic shock [1]. DGI primarily occurs in individuals with an asymptomatic untreated primary infection, most
57 often female, although some studies have shown an association with males [2-4]. Early diagnosis and
58 treatment are required to avert significant morbidity.

59 Both host and *N. gonorrhoeae* strain-related factors can predispose to DGI. Host associated risk factors include
60 recent menstruation, pregnancy and complement deficiencies [5-7]. Several strain-related factors have been
61 proposed including exhibiting an arginine-hypoxanthine-uracil (AHU) auxotype, expressing particular phase-
62 variable variants of the pilus glycosyl transferase A (*pgtA*) gene, opacity genes, and harbouring a PIA class of
63 *porB* gene (as opposed to PIB) [8-14]. Gonococcal genetic island (GGI) is another speculated virulence factor
64 encoding a Type IV secretion system (T4SS) which plays a role in horizontal gene transfer [15]. However, except
65 for the PIA gene, evidence to support the strain-related factors is limited. For example, an early study of DGI-
66 causing gonococci in Australia found that none were of the AHU auxotype, while a later Australian study found
67 no strong association with the phase-variable allele of the *pgtA* gene, subsequently referred to as the *pglA*

68 gene[16,17]. Previous studies assessing strain-related factors associated with DGI are limited by sample size
69 and/or lack of comparison to non-DGI isolates.

70 We sought to assess the genetic diversity of *N. gonorrhoeae* isolates collected in Queensland from January
71 2010 to August 2015 and to determine factors associated with DGI in Queensland. In addition, we utilised WGS
72 to gain insight to any existing strain-related factors which may have contributed to the occurrence of DGI.

73 **METHODS**

74 ***N. gonorrhoeae* isolates from Queensland**

75 From 2010 to 2015, the Australian state of Queensland reported 16,506 gonococcal infections over the 6 years,
76 equivalent to an average notification rate of 60 cases per 100,000 population per year [18]. Approximately 75%
77 of these notifications were diagnosed by NAAT only, with no isolate available for further testing. Diagnostic
78 methods used varied across the state, with 80% of cases in the northern Queensland regions diagnosed by
79 NAAT only, as opposed to 70% of cases from the rest of the state; with larger variations of between 58% and to
80 84% for individual health service districts. A total of 3953 *N. gonorrhoeae* isolates were included in this study,
81 isolated from specimens collected between January 2010 and August 2015 in pathology laboratories servicing
82 Queensland and surrounding areas and subsequently referred to the state reference laboratory at Queensland
83 Health Forensic and Scientific Services. One isolate per patient episode, defined as not collected within one
84 month of a previously included strain, was included. Data collected for each isolate included date of specimen
85 collection, age, sex, postcode of residence and specimen type. To identify disease prevalence in specific age
86 groups isolates from males and females were grouped into two groups, <30 years and ≥30 years. Postcode of
87 residence was used to assign broad geographic region categories of NQ (northern Queensland) and SEQ (south-
88 east Queensland) and other (sparsely populated central Queensland, interstate, or overseas). DGI was defined
89 where the organism was isolated from blood culture, joint fluid and/or tissue.

90 **NG-MAST typing and phylogenetic analysis**

91 Crude DNA extracts of all the *N. gonorrhoeae* isolates received in the study period were routinely subjected to
92 *N. gonorrhoeae* multi-antigen sequence typing (NG-MAST) as previously described [19]. These extracts were
93 prepared by boiling 400µL of TE buffer containing a loopful (1µL) of pure *N. gonorrhoeae* colonies at 100°C for
94 10 minutes. NG-MAST comprises DNA sequencing of partial *tbpB* and *porB* genes and subsequent analysis via
95 an online database to assign allele and sequence types (www.ng-mast.net). The *porB* sequence data from the
96 NG-MAST was analysed to assign either PIA or PIB class [20]. The analysis was based on a phylogenetic
97 assessment, and comparison with previously recognised PIA and PIB sequences from GenBank.

98 **WGS and bioinformatic analysis**

99 To investigate strain-related factors associated with DGI, we selected 16 isolates from 8 different NG-MAST
100 types which were prevalent in DGI, in this study. Two strains from each NG-MAST were selected, comprising
101 both DGI and non-DGI strains. DNA was extracted from isolates using the QIAasymphony SP, using the DSP DNA
102 minikit (Qiagen, Germany), as per manufacturer's guidelines. WGS was performed on the Illumina NextSeq 500
103 platform (Illumina, CA, USA) using NextSeq 500 Mid Output V2 kit (Illumina) with Nextera XT library
104 preparation. Reads were trimmed with Trimmomatic (Version 0.36) [21], corrected and assembled with Spades
105 (Version 3.10.1) (<https://github.com/ablab/spades>) [22], and assemblies uploaded to pubMLST to determine
106 presence/absence of the gonococcal genetic island [23], and analysed with Ridom SeqSphere+ 4.1.0 (Ridom
107 GmbH, Germany) using alleles from 1,649 *N. gonorrhoeae* cgMLST v1.0 loci [24], and *Neisseria* spp. MLST [25].
108 WGS assemblies are available on pubMLST with ID numbers 52753-52768. WGS raw sequence files and
109 associated metadata have been submitted to the European Nucleotide Archive with Project Accession number
110 PRJEB52601.

111 **Statistical analysis**

112 Descriptive analysis was performed using Microsoft Excel. Annual rates of reported cases were computed by
113 using the number of cases reported as numerators, and statistics Queensland yearly population as
114 denominators. Categorical variables were examined using the Fischer's Exact test performed in GraphPad Prism

115 7 (GraphPad Software Inc., California). Odds ratios (OR) with 95% confidence intervals were obtained from
 116 logistic regression models in Microsoft Excel to quantify associations between independent variables and
 117 outcome. P values of <0.05 were considered statistically significant.

118 Patient and public involvement

119 There was no patient or public involvement in the study.

120 RESULTS

121 Demographics and *N. gonorrhoeae* isolates

122 The total 3,953 *N. gonorrhoeae* isolates in this study from January 2010 to August 2015 consisted of genital
 123 (n=3,099; 78.3%), invasive (n=64; 1.6%), anorectal (n=456; 11.5%), oropharyngeal (n=233; 5.8%), ocular (n=31;
 124 0.7%), and other/not specified (n=70; 1.7%) specimen types, as listed in Supplementary Data Table 1. Overall,
 125 majority of these isolates were reported in SEQ (n= 2403; 60.7%), followed by NQ (n=1193; 30.1%) and other
 126 regions (sparsely populated central Queensland, interstate, or overseas) which constituted of 9% (n=357) of
 127 the total cases. The isolates comprised 73% (n=2898) from males (62.9 cases per 100,000 population) and 27%
 128 (n=1055) from females (22.9 cases per 100,000 population). Further breakdown into age groups showed that
 129 20.4% (n=808) gonococcal infections were represented by females <30 years of age and 5.9% of infections
 130 were reported in females ≥30 years of age. Similar trend was observed in males where 44.3% (n=1754) of *N.*
 131 *gonorrhoeae* infections were noted in males <30 year of age and 28.3% (n=1119) of infections were present in
 132 males ≥30 years of age. PIB class of porB was assigned to 72.7% (n=2875) of isolates whereas 27.3% (n=1078) of
 133 the isolates belonged to porB class PIA. Table 1 shows a breakdown for all strains by PIA/PIB, NQ/SEQ, and age
 134 group.

135 **Table 1: Demographics of *N. gonorrhoeae* isolates, Queensland January 2010 to August 2015**

Demographics	n	Percentage (%) of total
All cases	3953	100

porB Class	PIA	1078	27.3
	PIB	2875	72.7
Geographic location	NQ	1193	30.1
	SEQ	2403	60.7
	Others	357	9.0
Sex	F	1055	26.6
	M	2898	73.3
Age groups	<30 Female	808	20.4
	≥30 Female	234	5.9
	<30 Male	1754	44.3
	≥30 Male	1119	28.3
	Age not specified	38	0.9

NG-MAST typing and phylogenetic analysis

Among the 3,953 isolates tested, 574 alleles of *porB* gene were identified, the most prevalent of which was the 4101 allele, present in 441 isolates (11.1%). The *tbpB* gene was represented by 250 alleles with the most frequent allele was 29, detected in 653 isolates (16.5%). Combinations of *porB* and *tbpB* alleles resulted in 823 NG-MAST types. Overall ST6876 was the most common NG-MAST type, detected in 302 isolates (7.6%). It was also the most prevalent in years 2010 and 2011, represented by 126 (16.1%) and 109 (14.4%) isolates, respectively. In 2012 and 2013, ST21 became more prevalent, represented by 8.6% and 6.0% of the isolates collected in those years. In 2014 and 2015 (up to August), ST4186 was found with high frequency with 7.1% and 10.1% of the isolates, respectively. 771 STs were represented by only one isolate, and these STs accounted for between 16.8% and 23.3% of total isolates each year. Table 2 shows a summary of the most frequent alleles and types over the five years.

149
1
2
3 150
4
5
6
7 151
8
9
10 152
11
12
13 153
14
15
16 154
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

155 **Table 2: NG-MAST typing of isolates collected in Queensland from January 2010 to August 2015**

Year	Number of <i>N. gonorrhoeae</i> isolates	Number of <i>porB</i> alleles	Most frequent <i>porB</i> alleles	Number of <i>tbpB</i> alleles	Most frequent <i>tbpB</i> alleles	Number of NG-MAST types	Most frequent NG-MAST types	<i>porB</i> Class	Invasive (DGI) isolates *
2010	782	165	porB 4101 (18.7%)	87	tbpB 29 (17.6%)	208	6876 (16.1%)	PIA - 255 (32.6%) PIB - 527 (67.3%)	12 (1.5%)
			porB 2280 (5.3%)		tbpB 1330 (16.3%)		6863 (5.4%)		
			porB 908 (4.7%)		tbpB 1329 (8.4%)		1407 (4.7%)		
			porB 1808 (4.4%)		tbpB 110 (6.6%)		2992 (4.4%)		
			porB 4143 (3.7%)		tbpB 349 (6.1%)		6940 (3.7%)		
2011	754	157	porB 4101 (17.9%)	85	tbpB 29 (24.0%)	206	6876 (14.4%)	PIA - 240 (31.8%) PIB - 514 (68.1%)	8 (1.0%)
			porB 1808 (8.8%)		tbpB 1330 (15.5%)		2992 (8.8%)		
			porB 4099 (5.3%)		tbpB 349 (7.0%)		6879 (4.7%)		
			porB 14 (4.7%)		tbpB 33 (6.7%)		21 (4.4%)		
			porB 4104 (3.7%)		tbpB 1329 (6.1%)		6937 (3.2%)		
2012	680	156	porB 4101 (12.2%)	91	tbpB 29 (19.7%)	203	21 (8.6%)	PIA - 195 (28.6%) PIB - 485 (71.3%)	10 (1.4%)
			porB 14 (8.6%)		tbpB 349 (12.3%)		2992 (7.6%)		
			porB 4099 (7.7%)		tbpB 33 (10.8%)		6879 (7.5%)		
			porB 1808 (7.6%)		tbpB 1330 (9.1%)		6876 (7.0%)		
			porB 4104 (5.5%)		tbpB 1329 (7.0%)		6937 (4.1%)		
2013	650	167	porB 1808 (7.2%)	93	tbpB 29 (18.9%)	217	21 (6.0%)	PIA - 160 (24.6%) PIB - 490 (75.3%)	10 (1.5%)
			porB 4101 (6.7%)		tbpB 349 (8.3%)		4822 (6.0%)		
			porB 1903 (6.1%)		tbpB 33 (7.5%)		6879 (5.3%)		
			porB 14 (6.0%)		tbpB 110 (6.9%)		4186 (5.2%)		
			porB 4099 (5.3%)		tbpB 241 (6.9%)		5533 (4.0%)		
2014	633	147	porB 1808 (14.6%)	90	tbpB 241 (8.5%)	201	4186 (7.1%)	PIA - 140 (22.1%) PIB - 493 (77.8%)	18 (2.8%)
			porB 2569 (7.2%)		tbpB 29 (7.8%)		9654 (5.6%)		
			porB 147 (6.4%)		tbpB 4 (7.1%)		4244 (4.8%)		
			porB 4101 (4.5%)		tbpB 110 (6.1%)		10039 (3.7%)		
			porB 5912 (3.7%)		tbpB 1744 (6.0%)		5004 (2.3%)		
2015**	454	115	porB 1808 (12.1%)	74	tbpB 241 (16.5%)	154	4186 (10.1%)	PIA - 87 (19.1%) PIB - 367 (80.8%)	6 (1.3%)
			porB 2569 (10.1%)		tbpB 4 (6.4%)		4244 (5.2%)		
			porB 147 (8.14%)		tbpB 29 (5.9%)		9654 (4.4%)		
			porB 2656 (5.0%)		tbpB 893 (5.7%)		9909 (3.9%)		
			porB 543(4.1%)		tbpB 1744 (5.3%)		11821 (3.7%)		

156 *Percentage of total isolates

157 **Data collected up until August 2015

158

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

159 **Disseminated gonococcal infection**

160 From January 2010 to August 2015, 64 DGI-related isolates were received by the reference laboratory,
161 comprising 1.6% of total isolates; 49 cases (76.6%) were diagnosed from joint samples and 15 (23.4%) from
162 blood samples. This study only had access to cultured gonococcal isolates, so any DGI cases diagnosed by NAAT
163 only are not considered here. A summary of the demographics, *porB* class types and strain types (n=8)
164 associated with DGI cases is provided in Table 3. Even though the majority of total gonococcal isolates were
165 from males, DGI was significantly more likely in females (OR 4.72, $p<0.0001$), particularly in those aged <30
166 years (OR 13.02, $p<0.0001$) and in older males aged >30 years (OR 6.04, $p<0.0001$) when compared to their
167 younger counterparts. The majority of DGI cases (n=50; 78%) originated from the north Queensland, and cases
168 from this region had higher odds of being associated with DGI (OR 8.5, $p<0.0001$). A total of 31 STs of the total
169 823 were observed amongst the 64 DGI cases. PIA *porB* type was significantly associated with DGI (OR 33.23,
170 $p<0.0001$), and accounted for 59 (92.2%) of the 64 DGI cases. Seven of the prevalent NG-MASTs in DGI (ST758,
171 ST6886, ST6937, ST6939, ST7126, ST8712, and ST10711), all with PIA class of *porB*, were found to be
172 individually associated with DGI (Table 3). However, the most prevalent NG-MAST in this study ST6876 (n=302),
173 which is also PIA class of *porB*, was not found to be associated with DGI (n=6) (OR 1.2, $p=0.6$).

Table 3: Demographic factors, *porB* type and NG-MAST types associated with disseminated gonococcal infection (DGI) in Queensland (January 2010 to August 2015)

Risk factor		Non-DGI	DGI	Total	DGI as percentage (%)	Univariate OR	p value
porB class	PIA	1019	59	1078	5.5	33.23	<0.0001
	PIB	2870	5	2875	0.2	0.03	
Geographic location	NQ	1143	50	1193	4.2	8.5	<0.0001
	SEQ	2394	9	2403	0.4	0.1	
	Other	352	5	357	1.4	0.85	
Sex	Female	1015	40	1055	3.8	4.72	<0.0001
	Male	2874	24	2898	0.8	0.2	
Age group (years)	<30 Female	779	29	808	3.58	13.02	<0.0001
	<30 Male	1749	5	1754	0.2	0.07	
	≥30 Female	223	11	234	4.7	2.85	0.01
	≥30 Male	1100	19	1119	1.69	0.35	
	<30 Female	779	29	808	3.58	0.75	0.44
	≥30 Female	223	11	234	4.7	1.32	
	<30 Male	1749	5	1754	0.2	0.16	<0.0001
	≥30 Male	1100	19	1119	1.69	6.04	
	Age not specified	38	0	38	0.0		
Prevalent NG-MAST	ST758	17	2	19	10.5	3.67	0.03
	ST6876	296	6	302	2.0	1.2	0.6

types	ST6886	30	3	33	9.1	6.3	0.001
	ST6937	80	14	94	14.9	13.3	<0.0001
	ST6939	34	3	37	8.1	5.57	0.02
	ST7126	22	3	25	12.0	8.6	0.007
	ST8712	17	5	22	22.7	19.3	<0.0001
	ST10711	15	3	18	16.7	12.7	0.002
	Other STs	3378	25	3403	0.7	0.09	
	Total	3889	64	3953	1.6%		

Whole genome sequencing

Figure 1 shows a core genome phylogeny of the 16 strains from 8 different NG-MAST, all of which were PIA types, selected for WGS. The four ST6886 and ST6937 strains contained phase variable *pglA* (NEIS0213) alleles with long homopolymeric tracts of Gs, while the others did not. These four strains grouped together by cgMLST, despite one of them sharing an MLST profile with other strains that did not form part of this group. Only one of the 16 strains sequenced did not possess the gonococcal genetic island.

DISCUSSION

This study investigated the burden of gonococcal infections in Queensland and identified those most at risk of developing DGI. The increasing gonorrhoea rates among males could be a result of rapidly increasing rates of gonorrhoea in the MSM population. Another explanation would be that gonorrhoea is more symptomatic in men and as a result they are more likely to seek health care. In this study, we applied *N. gonorrhoeae* NG-MAST genotyping to a large, diverse, consecutively collected *N. gonorrhoeae* isolate collection in a setting where DGI is not uncommon and used WGS to investigate other strain-related factors. We have used a dataset of strains that encompassed both metropolitan and regional populations and has subsequently highlighted different

1
2 197 populations vulnerable to DGI. We observed a higher likelihood of DGI in females, in cases reported in NQ
3
4 198 when compared to SEQ, and with strains harbouring the PIA gene. This finding agrees with previous studies
5
6 199 suggesting female predominance [2] but contradicts a more recent study from the Northern Territory of
7
8
9 200 Australia which did not show any significant association between DGI and sex [26], but did not examine strain-
10
11 201 related factors such as PIA/PIB. Moreover, our data may indicate that DGI is associated with certain PIA gene
12
13 202 positive NG-MAST types, suggesting that additional mechanisms possessed by particular PIA bearing genotypes
14
15 203 may be at play. PIA has previously been reported to be associated with DGI due to a diminished inflammatory
16
17
18 204 response, which increases the chances that a mucosal infection may go untreated and therefore progress to
19
20 205 DGI [12].
21
22

23 206 Our data identified *pglA* phase variation present within certain NG-MAST types that were associated with DGI,
24
25 207 however further studies with larger diversity of strain collections are required, as this finding is inconsistent
26
27
28 208 with the work of Power *et al* [17]. Our sequencing work did not show any evidence that DGI is associated with
29
30 209 the gonococcal genetic island as seen by Dillard *et al* [15], however with the limited number of strains we
31
32 210 sequenced, no statistical significance can be drawn and further studies are required to confirm or refute this.
33
34 211 Data on the co-existence of genital infections for DGI cases was not consistently available, however there were
35
36 212 DGI cases that did not have a genital infection recorded in the dataset. Absence of a genital infection suggests
37
38
39 213 cases may have cleared a mucosal infection before progressing to DGI, which would be more likely for
40
41 214 asymptomatic infections in females rather than via anorectal injury infection in males.
42
43

44 215 The majority of gonorrhoea cases yielding an isolate are represented by males who continue to have higher
45
46 216 notification rates than females in Queensland. DGI is not a rare occurrence, being noted in 1.6% of culture-
47
48
49 217 positive cases, and younger females showing higher rates than males. High DGI rates among younger women
50
51 218 are concerning as infertility is one of the potential outcomes of untreated gonorrhoea infection, which has
52
53 219 downstream social and economic impacts. Genotyping techniques such as NG-MAST and WGS are proving
54
55
56
57
58
59
60

1
2 220 instrumental in providing an insight into the population structure of *N. gonorrhoeae*, and genetic mechanisms
3
4 221 of pathogenesis, such as for DGI.
5

7 222 **Contributors**

8
9
10 223 Amy Jennison and David Whiley conceptualised the study. Christine Guglielmino conducted the laboratory
11
12 224 investigation. Christine Guglielmino, Sumeet Sandhu, Colleen Lau, Cameron Buckley and Ella Trembizki
13
14 225 performed formal data analysis. All authors contributed to the writing and review of the manuscript.
15
16
17

18 226 **Acknowledgments**

19
20
21 227 This publication made use of the Neisseria Multi Locus Sequence Typing website ([https://pubmlst.org/](https://pubmlst.org/neisseria/)
22
23 228 neisseria/) developed by Keith Jolley and sited at the University of Oxford [23]. The development of this site
24
25 229 has been funded by the Wellcome Trust and European Union. We thank all laboratories for referring isolates
26
27 230 included in this study, and Public Health Microbiology Staff for technical work.
28
29
30

31 231 **Competing interests**

32
33
34 232 None.
35
36
37

38 233 **Data availability statement**

39
40
41 234 WGS raw sequence files and associated metadata have been submitted to the European Nucleotide Archive
42
43 235 with Project Accession number PRJEB52601.
44
45

46 236 **Funding**

47
48
49
50 237 This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-
51
52 238 profit sectors.
53
54

55 239 **Transparency declarations**

1
2 240 D.M.W. reports research funding from SpeedX Pty Ltd and is supported by a Queensland Advancing Clinical
3
4 241 Research Fellowship from the Queensland Government. E.T is holding an NHMRC Early Career Fellowship. CLL
5
6 242 is supported by an NHMRC Investigator Grant (APP1193826).
7
8

9
10 243 **Ethics approval**

11
12
13 244 The study was approved by Forensic and Scientific Services Human Ethics Committee (FSS-HEC, EC00305). HEC
14
15 245 Ref Number HEC18_01.
16
17

18 246 **REFERENCES**

- 19
20
21 247 1 Thiéry G, Tankovic J, Brun-Buisson C, et al. Gonococemia associated with fatal septic shock. *Clin Infect Dis*
22
23 2001;32:92-93.
24 248
25
26
27 249 2. Tuttle CS, Van Dantzig T, Brady S, et al. The epidemiology of gonococcal arthritis in an Indigenous Australian
28
29 250 population. *Sex Transm Infect* 2015;91:497-501.
30
31
32 251 3. Suzaki A, Hayashi K, Kosuge K, et al. Disseminated gonococcal infection in Japan: a case report and literature
33
34 review. *Inter Med* 2011;50:2039-2043.
35 252
36
37
38 253 4. Belkacem A, Caumes E, Ouanich J, et al. Changing patterns of disseminated gonococcal infection in France:
39
40 254 cross-sectional data 2009–2011. *Sex Transm Infect* 2013; 9:613-615.
41
42
43 255 5. Bleich AT, Sheffield JS, Wendel Jr GD, et al. Disseminated gonococcal infection in women. *Obstet Gynecol*
44
45 2012;119:597-602.
46 256
47
48
49 257 6. Phupong V, Sittisomwong T, Wisawasukmongchol W. Disseminated gonococcal infection during pregnancy.
50
51 258 *Gynecol and Obstet* 2005;273:185-186.
52
53
54 259 7. Petersen BH, Lee TJ, Snyderman R, et al. *Neisseria meningitidis* and *Neisseria gonorrhoeae* bacteremia
55
56 associated with C6, C7, or C8 deficiency. *Annals Int Med* 1979;90:917-920.
57 260
58
59
60

- 1
2 261 8. Banerjee A, Wang R, Supernavage SL, et al. Implications of phase variation of a gene (*pgtA*) encoding a pilin
3
4 262 galactosyl transferase in gonococcal pathogenesis. *J of Exp Med* 2002;196 (2):147-162.
5
6
7 263 9. Roth A, Mattheis C, Muenzner P, et al. Innate recognition by neutrophil granulocytes differs between
8
9 264 *Neisseria gonorrhoeae* strains causing local or disseminating infections. *Infect Immun* 2013;81:2358-2370.
10
11
12
13 265 10. Knapp JS, Holmes KK. Disseminated gonococcal infections caused by *Neisseria gonorrhoeae* with unique
14
15 266 nutritional requirements. *J Infect Dis* 1975;132:204-208.
16
17
18 267 11. Brunham RC, Plummer F, Slaney L, et al. Correlation of auxotype and protein I type with expression of
19
20 268 disease due to *Neisseria gonorrhoeae*. *J Infect Dis* 1985;152:339-343.
21
22
23
24 269 12. van Putten JP, Duensing TD, Carlson J. Gonococcal invasion of epithelial cells driven by P. IA, a bacterial ion
25
26 270 channel with GTP binding properties. *J Exp Med* 1998;188:941-952.
27
28
29 271 13. Plummer FA, Chubb H, Simonsen JN, et al. Antibodies to opacity proteins (Opa) correlate with a reduced
30
31 272 risk of gonococcal salpingitis. *J Clin Invest* 1994;93:1748-1755.
32
33
34
35 273 14. Ram S, Cullinane M, Blom AM, et al. Binding of C4b-binding protein to porin: a molecular mechanism of
36
37 274 serum resistance of *Neisseria gonorrhoeae*. *J Exp Med* 2001;193:281-296.
38
39
40 275 15. Dillard JP, Seifert HS . A variable genetic island specific for *Neisseria gonorrhoeae* is involved in providing
41
42 276 DNA for natural transformation and is found more often in disseminated infection isolates. *Mol Micro*
43
44 2001;41:263-277.
45
46
47
48 278 16. Tapsall J, Phillips E, Shultz T, et al. Strain characteristics and antibiotic susceptibility of isolates of *Neisseria*
49
50 279 *gonorrhoeae* causing disseminated gonococcal infection in Australia. *Int J STD & AIDS* 1992;3:273-277.
51
52
53
54
55
56
57
58
59
60

- 1
2 280 17. Power PM, Ku SC, Rutter K, et al. The phase-variable allele of the pilus glycosylation gene *pglA* is not
3
4 281 strongly associated with strains of *Neisseria gonorrhoeae* isolated from patients with disseminated gonococcal
5
6 282 infection. *Infect Immun* 2007;75:3202-3204.
7
8
9
10 283 18. National Notifiable Diseases Surveillance System. Australian Government Department of Health.
11
12 284 <http://www9.health.gov.au/cda/source/cda-index.cfm>. Accessed 16 July 2019
13
14
15 285 19. Martin IMC, Ison CA, Aanensen DM, et al. Rapid sequence-based identification of gonococcal transmission
16
17 286 clusters in a large metropolitan area. *J Infect Dis* 2004;189:1497-1505.
18
19
20
21 287 20. Van Der Ley P, Heckels JE, Virji M, Hoogerhout P, Poolman J . Topology of outer membrane porins in
22
23 288 pathogenic *Neisseria* spp. *Infect Immun* 1991;59:2963-2971.
24
25
26 289 21. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics*
27
28 290 2014;30:2114-2120.
29
30
31
32 291 22. Bankevich A, Nurk S, Antipov D, et al. SPAdes: a new genome assembly algorithm and its applications to
33
34 292 single-cell sequencing. *J Comput Biol* 2012;19:455-477.
35
36
37 293 23. Jolley KA, Maiden MC. BIGSdb: scalable analysis of bacterial genome variation at the population level. *BMC*
38
39 294 *Bioinformatics* 2010;11:595.
40
41
42
43 295 24. Harrison OB, Cehovin A, Skett J, et al. *Neisseria gonorrhoeae* population genomics: Use of the gonococcal
44
45 296 core genome to improve surveillance of antimicrobial resistance. *J Infect Dis* 2020;222:1816-1825.
46
47
48 297 25. Maiden MCJ, Bygraves JA, Feil E, et al. Multilocus sequence typing: A portable approach to the
49
50 298 identification of clones within populations of pathogenic microorganisms. *Proc Natl Acad Sci U S A*
51
52 299 1998;95:3140-3145.
53
54
55
56
57
58
59
60

1
2 300 26. Birrell JM, Gunathilake M, Singleton S, et al. Characteristics and impact of disseminated gonococcal
3
4 301 infection in the 'Top End' of Australia. *Am J Trop Med Hyg* 2019;101:753-760.
5

6
7 302 27. Letunic I, Bork P .Interactive tree of life (iTOL) v3: an online tool for the display and annotation of
8
9 303 phylogenetic and other trees. *Nuc Acids Res* 2016;44: 242-245.
10
11

12
13 304
14
15

16 305 **Figure legend**
17

18
19 306 **Figure 1: Core genome maximum likelihood phylogeny of 16 PIA strains of *N. gonorrhoeae* from Queensland**
20
21 307 **based on cgMLST**
22
23

24
25 308 The tree is rooted at centre-point and annotated with strain ID, NG-MAST associated with DGI, and sequence
26
27 309 types derived from MLST and NG-MAST, with presence/absence of phase variable *pglA* and gonococcal genetic
28
29 310 island. The phylogenetic distance is indicated by the length of the horizontal lines. Visualised with iTOL [27].
30
31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58


59

60

Tree scale: 0.001

Key

- Present
- Absent



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	3
Methods			
Study design	4	Present key elements of study design early in the paper	4-5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	4
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4
Bias	9	Describe any efforts to address potential sources of bias	6, 12
Study size	10	Explain how the study size was arrived at	4
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5,6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	5
		(b) Describe any methods used to examine subgroups and interactions	5
		(c) Explain how missing data were addressed	NA
		(d) If applicable, describe analytical methods taking account of sampling strategy	NA
		(e) Describe any sensitivity analyses	NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	4
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	4
		(b) Indicate number of participants with missing data for each variable of interest	4
Outcome data	15*	Report numbers of outcome events or summary measures	8-11
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make	6,8,10,11

		clear which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	10
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	10
Discussion			
Key results	18	Summarise key results with reference to study objectives	12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12
Generalisability	21	Discuss the generalisability (external validity) of the study results	12
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.